2024

• Cellular and humoral response to SARS-CoV-2 vaccine BNT162b2 in adults with Chronic Kidney Disease G4/5.
  Rosdahl et al., New Microbes & New Infections (2024) - PMID: 39282145
  Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
• MVA-based vaccine candidates expressing SARS-CoV-2 prefusion-stabilized spike proteins of the Wuhan, Beta or Omicron BA. 1 variants protect transgenic K18-hACE2 mice against Omicron infection and elicit robust and broad specific humoral and cellular immune responses
  Pérez et al., Frontiers in Immunology (2024) - PMID: 39267752
  Product used: PepMix™ SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron)
• SARS-CoV-2 spike-specific nasal-resident CD49a+CD8+ memory T cells exert immediate effector functions with enhanced IFN-γ production
  Rha et al., Nature Communications (2024) - PMID: 39333516
  Product used: PepMix™ SARS-CoV-2 (NCAP)
• Long-term cellular immunity of vaccines for Zaire Ebola Virus Diseases
  Wiedemann et al., Nature Communications (2024) - PMID: 39227399
  Products used: PepMix™ Zaire Ebola (GP/Mayinga-76)
• Stem cell memory EBV-specific T cells control EBV tumor growth and persist in vivo
  Palianina et al., Science Advances (2024) - PMID: 39178248
  Products used: PepMix™ Collection EBV (25ug/peptide), PepMix™ EBV (LMP2), PepMix™ EBV (BZLF1), PepMix™ EBV (EBNA1), PepMix™ Human Adenovirus 5 (Penton Protein), PepMix™ Human Adenovirus 5 (Hexon Protein), PepMix™ Human CMV (pp65), PepMix™ Human CMV (IE-1), PepMix™ BKV (capsid protein VP1), PepMix™ HHV6 (U90), PepMix™ HHV6 (U54), PepMix™ BKV (large T antigen)
• Repeated COVID-19 Vaccination Drives Memory T- and B-cell Responses in Kidney Transplant Recipients: Results From a Multicenter Randomized Controlled Trial
  Malahe et al., Transplantation (2024) - PMID: 38902860
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• Impaired T cells and "memory-like" NK-cell reconstitution is linked to late-onset HCMV reactivation after letermovir cessation
  Lauruschkat et al., Blood Advances (2024) - PMID: 38315873
  Products used: PepMix™ HCMVA (pp65), PepMix™ HIV-1 (NEF) Ultra
• Lipo-pam™ adjuvanted herpes zoster vaccine induces potent gE-specific cellular and humoral immune responses
  Soo-Kyung Jeong et al., Vaccines (2024) - PMID: 39154056
  Product used: PepMix™ VZV (gE)
• Variant-proof high affinity ACE2 antagonist limits SARS-CoV-2 replication in upper and lower airways
  Gagne et al., Nature Communications (2024) - PMID: 39134521
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2) 
• Mucosal adenovirus vaccine boosting elicits IgA and durably prevents XBB.1.16 infection in nonhuman primates
  Gagne et al., Nature Immunology (2024) - PMID: 39227514
  Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2), PepMix™ SARS-CoV-2 (NCAP)
• Endurance Exercise Does Not Exacerbate Cardiac Inflammation in BALB/c Mice Following mRNA COVID-19 Vaccination
  Eens et al., Vaccines (2024)
  Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
• Asian Flush Gene Variant Enhances Cellular Immunogenicity of COVID‐19 Vaccine: Prospective Study in the Japanese General Population
  Bogahawaththa et al., Vaccines (2024)
  Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
• Immunogenicity and biodistribution of lipid nanoparticle formulated self-amplifying mRNA vaccines against H5 avian influenza
  Cui et al., Vaccines (2024) - PMID: 39097672
  Product used: PepMix™ Influenza A (HA/Indonesia (H5N1))
• Infectious diseases and their impact on the development and progression of renal graft dysfunction: Optimizing the preventive approach to viral infections
  Drenko, Dissertation (2024)
  Products used: PepMix™ Human CMV (IE-1), PepMix™ Human CMV (pp65)
• Heterologous mRNA/MVA delivering trimeric-RBD as effectivevaccination regimen against SARS-CoV-2: COVARNA Consortium
  Marcos-Villar et al., Emerging Microbes & Infections
  Product used: PepMix™ SARS-CoV-2 (S-RBD)
• Interleukin‐2‐mediated CD4 T‐cell activation correlates highly with effective serological and T‐cell responses to SARS‐CoV‐2 vaccination in people living with HIV
  Gupta et al., Journal of Medical Virology (2024) - PMID: 39056205
  Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
• Cytokine profile of anti-spike CD4+ T cells predicts humoral and CD8+ T cell responses after anti-SARS-CoV-2 mRNA vaccination
  Benhamouda et al., iScience (2024) 
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• Repeated COVID-19 Vaccination Drives Memory T- and B-cell Responses in Kidney Transplant Recipients: Results From a Multicenter Randomized Controlled Trial
  Malahe et al., Transplantation (2024) 
  Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• Kinetics of pro- and anti-infammatory spike-specifc cellular immune responses in long-term care facility residents after COVID-19 mRNA primary and booster vaccination: a prospective longitudinal study in Japan
  Kagugawa et al., Immunity and Ageing (2024) - PMID: 38909235
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• Strategies to determine positive anti-SARS-CoV-2 memory T lymphocyte response during the evolution of an epidemic
  Nel et al, Journal of Immunological Models (2024)
  Products used: PepMix SARS-CoV-2 (NCAP), PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• Switching disease-modifying therapies from sphingosine-1-phosphate receptor modulators to natalizumab or dimethyl fumarate restores immune responses after SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis
  Kanakura et al., Clinical Neurology and Neurosurgery (2024) - PMID: 38901377
  Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
• Intranasal SARS-CoV-2 Omicron variant vaccines elicit humoral and cellular mucosal immunity in female mice
  Slamaning et al., EBioMedicine (2024) - PMID: 38848648
  Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein), PepMix™ SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron)
• Heightened Epstein-Barr virus immunity and potential cross-reactivities in multiple sclerosis
  Thomas et al., PLoS Pathogens (2024) - PMID: 38843296
  Products used: PepMix EBV (EBNA1)
• Identification of soluble biomarkers that associate with distinct manifestations of long COVID
  Buggert et al., Research Square (2024) 
  Product used: PepMix EBV (BARF1), PepMix EBV (BRLF1), PepMix EBV (BMLF1), PepMix EBV (BZLF1), PepMix EBV (EBNA1), PepMix EBV (EBNA2), PepMix EBV (EBNA3a), PepMix EBV (EBNA3b), PepMix EBV (EBNA3c), PepMix EBV (LMP2), PepMix Human CMV (pp65), PepMix Human CMV (IE-2), PepMix Human CMV (IE-1)
• A vaccine targeting antigen-presenting cells through CD40 induces protective immunity against Nipah disease
  Pastor et al., Cell Reports Medicine (2024) - PMID: 38471503
  Products used: PepMix Nipah Virus (Nucleoprotein N), Nipah virus (Glycoprotein G), Nipah Virus (Fusion Glycoprotein F0) and ECD
• Rejection resistant CD30.CAR-modified Epstein-Barr virus specific T cells as an offthe-shelf platform for CD30+ lymphoma
  Quach et al., Molecular Therapy: Oncology (2024) 
  Products used: PepMix EBV (EBNA1), EBV (BZLF1), EBV (LMP1), EBV (LMP2)
• Cytomegalovirus UL44 protein induces a potent T-cell immune response in mice
  Mancebo et al., Antiviral Research (2024) 
  Products used: Custom PepMix CMV UL44, PepMix Human CMV (pp65)
• SARS-CoV-2-specific immune responses converge in kidney disease patients and controls with hybrid immunity
  Aguilar-Bretones et al., Vaccines (2024) 
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• An IL-10 homologue encoded by human cytomegalovirus is linked with the viral “footprint” in clinical samples
  Veld et al., Cytokine (2024) 
  Product used: PepMix Human CMV (IE-1)
• Imbalance of SARS-CoV-2-specific CCR6+ and CXCR3+ CD4+ T cells and IFN-γ + CD8+ T cells in patients with Long-COVID
  Martínez-Fleta et al., Clinical Immunology (2024) 
  Products used: PepMix SARS-CoV-2 (NCAP), PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• Optimizing SARS-CoV-2 vaccine responses in kidney transplant recipients: an urgent need
  Cheng et al., Microbiology Spectrum (2024) - PMID: 38747636
  Products used: PepMix SARS-CoV-2 (Spike B.1.617.2 / Delta), SARS-CoV-2 (Spike B.1.1.529 / BA.2 / Omicron)
• Modulation of innate immune response to mRNA vaccination after SARS-CoV-2 infection or sequential vaccination in humans
  Hellgren et al., JCI Insight (2024)
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• Intranasal vaccination with an NDVvectored SARS-CoV-2 vaccine protects against Delta and Omicron challenges
  Warner et al., Vaccines (2024) - PMID: 38782986
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• Kinetics of pro- and anti-inflammatory spike-specific T-cell responses in long-term care facility residents after COVID-19 mRNA primary and booster vaccination: A prospective longitudinal study in Japan
  Kakugawa et al., Research Square (2024)
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• Nasal vaccination of triple-RBD scaffold protein with flagellin elicits long-term protection against SARS-CoV-2 variants including JN.1
  Li et al., Signal Transduction and Targeted Therapy (2024) - PMID: 38678055
  Product used: PepMix SARS-CoV-2 (S-RBD)
• Gene replacement therapy in Bietti crystalline corneoretinal dystrophy: an open-label, single-arm, exploratory trial
  Wang et al., Signal Transductions and Targeted Therapy (2024) - PMID: 38653979
  Product used: PepMix AAV8 (Capsid protein)
• A bivalent COVID-19 mRNA vaccine, PTX-COVID19-M1.2, elicited broad immune responses and protected animals from SARS-CoV-2 Omicron subvariants infection
  Wang et al., Research Square (2024) 
  Products used: PepMix SARS-CoV-2 (Spike B.1.1.529 / BA.4 & BA.5 / Omicron), SARS-CoV-2 (Spike XBB.1.5)
• Immunogenicity and Protective Efficacy of Psoralen-Inactivated SARS-CoV-2 Vaccine in Nonhuman Primates
  Sanders et al., Vaccines (2024) 
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• Antigen clustering effect on immunogenicity in prefusion-stabilized spike-based COVID-19 vaccines
  Matthews et al., Research Square (2024) 
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1)
• Co-targeting EBV lytic as well as latent cycle antigens increases T-cell potency against lymphoma
  Sharma et al., Blood Advances (2024) 
  Products used: PepMix EBV (BZLF1), EBV (BRLF1), EBV (BMRF1)
• Third-party virus specific T cells for the treatment of double stranded DNA viral reactivation and PTLD after solid organ transplant
  Khoury et al., American Journal of Transplantation
  Products used: PepMix EBV (BZLF1), EBV (LMP2), EBV (EBNA1)
• Preclinical evaluation of two phylogenetically distant arenavirus vectors for the development of novel immunotherapeutic combination strategies for cancer treatment
  Raguz et al., Journal for Immunotherapy of Cancer (2024) - PMID: 38631709
  Products used: PepMix HPV 16 (E6), HPV 16 (E7)
• Lack of functional TCR-epitope interaction is associated with herpes zoster through reduced downstream T cell activation
  Boeren et al., Cell Reports (2024) - PMID: 38588339
  Product used: PepMix Influenza A (Neuroamidase /California (H1N1), VZV (gE), VZV (IE62)_2 subpools, VZV (IE63)
• COVID-19 vaccination induces distinct T-cell responses in pediatric solid organ transplant recipients and immunocompetent children
  Roznik et al., Vaccines (2024) 
  Products used: PepMix SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (Spike B.1.1.529 / BA.4 & BA.5 / Omicron)
• Innate Responses to the Former COVID-19 Vaccine Candidate CVnCoV and Their Relation to Reactogenicity and Adaptive Immunogenicity
  Wolz et al., Vaccines (2024) 
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• The Micro-Immunotherapy Medicine 2LPAPI® Displays Immune-Modulatory Effects in a Model of Human Papillomavirus Type-16 L1-Protein Capsid-Treated Human Peripheral Blood Mononuclear Cells and Antiproliferative Effects in a Model of Cervical Cancer Cells
  Jacques et al., Cancers (2024) 
  Product used: PepMix HPV16 (L1)
• From Vaccination to Infection: Mechanistic Studies of Immune Responses to SARS-COV-2
  Lenart, Dissertation (2024) 
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• Immunogenicity and efficacy of VLA2001 vaccine against SARS-CoV-2 infection in male cynomolgus macaques
  Galhaut et al., Communications Medicine (2024) - PMID: 38570605
  Products used: PepMix SARS-CoV-2 (S-RBD),  SARS-CoV-2 (NCAP)
• Evaluation of T Cell Response to SARS-CoV-2 in Kidney Transplant Recipients Receiving Monoclonal Antibody Prophylaxis and the Utility of a Bivalent mRNA Vaccine Booster Dose
  Bertrand et al., Microorganisms (2024) 
  Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2), SARS-CoV-2 (NCAP), SARS-CoV-2 (NS7A), SARS-CoV-2 (VEMP), SARS-CoV-2 (VME1), SARS-CoV-2 (Nsp3), CEFX Ultra SuperStim Pool
• Carrier-free mRNA vaccine induces robust immunity against SARS-CoV-2 in mice and non-human primates without systemic reactogenicity
  Abbasi et al., Molecular Therapy (2024) 
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA vaccination
  Verstegen et al., Multiple Sclerosis (2024) - PMID: 38548324
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• Children treated against lymphoid malignancies display diminished IFN-gamma producing T cells after polyclonal and Varicella zoster virus peptide activation
  Tiselius et al., Research Square (2024) 
  Product used: PepMix VZV (gE) and VZV (IE63)
• LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 study
  Musher et al., The Lancet Oncology (2024) - PMID: 38547893
  Product used: PepMix Human Adenovirus 26 (Hexon Protein) and Human Adenovirus 26 (Penton Protein)
• Comparable CD8+ T‐cell responses to SARS‐CoV‐2 vaccination in single‐cell transcriptomics of recently allogeneic transplanted patients and healthy individuals
  Tranter et al., Journal of Medical Virology (2024) 
  Product used: CEFX Ultra SuperStim Pool, PepMix SARS-CoV-2 (NCAP), SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2), SARS-CoV-2 AP3A (ORF3a), SARS-CoV-2 NS7A, SARS-CoV-2 NS8, Pan‐SARS-CoV-2 Select, and custom PepMix
• Generation of CRISPR-Cas9-edited Tacrolimus-resistant SARS-CoV-2-specific T-cells for adoptive cell therapy in transplant patients
  Peter, Dissertation (2024)
  Products used: PepMix CMVA (pp65), SARS-CoV-2 peptide pools (NCAP, Spike S1, Spike S2, VEMP, VME1, AP3a, NS6, NS7a, NS7b, NS8, ORF9b, ORF10, Y14)
• LVS ΔcapB-vectored multiantigenic melioidosis vaccines protect against lethal respiratory Burkholderia pseudomallei challenge in highly sensitive BALB/c mice
  Tullius et al., Vaccines (2024) 
  Product used: PepMix BKV (small T antigen)
• Bioinformatic, Biochemical, and Immunological Mining of MHC Class I Restricted T Cell Epitopes for a Marburg Nucleoprotein Microparticle Vaccine
  Harris et al., Vaccines (2024) 
• Development and Characterization of a Novel DC-Targeting Universal Influenza Vaccine
  Olukitibi et al., Dissertation (2024) 
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1)
•  A vaccine targeting antigen-presenting cells through CD40 induces protective immunity against Nipah disease 
  Pastor et al., Cell Reports Medicine (2024) - PMID: 38471503
  Products used: PepMix Nipah Virus (Nucleoprotein N), Nipah virus (Glycoprotein G),  Nipah Virus (Fusion Glycoprotein F0), custom PepMix Nipah ECD
• Single MVA-SARS-2-ST/N Vaccination Rapidly Protects K18-hACE2 Mice against a Lethal SARS-CoV-2 Challenge Infection
  Clever et al., Viruses (2024) 
  Product used: PepMix SARS-CoV-2 (NCAP), SARS-CoV-2 Antigen Peptide NCAP (LALLLLDRL), Antigen Peptide IFN-gR H-2 Kb (TSYKFESV)
• NFκB and NLRP3/NLRC4 inflammasomes regulate differentiation, activation and functional properties of monocytes in response to distinct SARS-CoV-2 proteins
  Tsukalov et al., Nature Communications (2024) - PMID: 38453949
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1), SARS-CoV-2 (NCAP)
• Comparable safety and non-inferior immunogenicity of the SARS-CoV-2 mRNA vaccine candidate PTX-COVID19-B and BNT162b2 in a phase 2 randomized, observer-blinded study
  Reiter et al., Scientific Reports (2024) - PMID: 38438427
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• Ad26.M.Env ZIKV vaccine protects pregnant rhesus macaques and fetuses against Zika virus infection
  Martinot et al., Research Square (2024) 
  Product used: PepMix ZIKV (E) Ultra, ZIKV (M) Ultra
• Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial.
  Pant et al., Nature Medicine (2024) - PMID: 38195752
  Product used: PepMix Pan-CMV Select, CMVA (pp65), SARS-CoV-2 (S-RBD)
• Cognate Antigen Engagement induces HIV-1 Expression in CD4+ T cells from people in long-term Art
  Moskovljevic et al., BioRxiv (2024) 
  Product used: PepMix™ HIV-1 (GAG) Ultra
• Bivalent mRNA COVID vaccines elicit predominantly cross-reactive CD4+ T cell clonotypes
  Sop et al., Cell Reports Medicine (2024) - PMID: 38423018
  Products used: PepMix SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (Spike B.1.1.529 / BA.4 & BA.5 / Omicron)
• Immune responses to SARS-CoV-2 mRNA vaccination in people with idiopathic CD4 lymphopenia
  Rocco et al., Translational and Clinical Immunology (2024) - PMID: 38344971
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• Multivalent cytomegalovirus glycoprotein B nucleoside modified mRNA vaccines did not demonstrate a greater antibody breadth
  Wang et al., Vaccines (2024) - PMID: 38378950
  Product used: custom PepStar, PepMix™ CMVA (UL55)
• Applying valency-based immuno-selection to generate broadly cross-reactive antibodies against influenza hemagglutinins
  Hinke et al., Nature Communications (2024) - PMID: 38346952
  Products used: PepMix™ Influenza A (HA/Puerto Rico/8/1934 H1N1), PepMix™ Influenza A (HA /California (H1N1))
• Integrating Machine Learning-Enhanced Immunopeptidomics and SARS-CoV-2 PopulationScale Analyses Unveils Novel Antigenic Features for Next-Generation COVID-19 Vaccines
  Caron et al., Research Square (2024) 
  Product used: PepMix™ HIV-1 (POL) Ultra
• Vaccines targeting ESR1 activating mutations elicit anti-tumor immune responses and suppress estrogen signaling in therapy resistant ER+ breast cancer
  Dailey et al., Human Vaccines & Immunotherapeutics (2024) - PMID: 38330990
  Products used: Custom PepMix (ESR1), PepMix™ HIV-1 (GAG) Ultra
• A Gamma-adapted subunit vaccine induces broadly neutralizing antibodies against SARS-CoV-2 variants and protects mice from infection
  Coria et al., Nature Communications (2024) - PMID: 38307851
  Products used: PepMix™ SARS-CoV-2 (S-RBD), PepMix™ SARS-CoV-2 (S-RBD P.1 / Gamma)
• Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer 
  Debie et al., Clinical Cancer Research (2024) - PMID: 36341493
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial
  Pant et al., Nature Medicine (2024) - PMID: 38195752
  Products used: PepMix™ SARS-CoV-2 (S-RBD),CEFSX Ultra SuperStim Pool, CEFT Pool, PepMix™ Pan-CMV Select, PepMix CMVA pp65, PepMix™ Pan-EBV Select, CEF Pool (standard) 
• MVA-based vaccine candidates encoding the native or prefusion-stabilized SARS-CoV-2 spike reveal differential immunogenicity in humans
  Mayer et al., Vaccines (2024) - PMID: 38278816
  Product used: CEF Pool (extended), PepMix™SARS-CoV-2 (Spike Glycoprotein) 
• Low pre-existing endemic human coronavirus (HCoV-NL63)-specific T cell frequencies are associated with impaired SARS-CoV-2-specific T cell responses in people living with HIV
  Ng'uni et al., Frontiers in Immunology (2024) - PMID: 38343437
  Products used: PepMix™ SARS-CoV-2 (Spike B.1.617.2 / Delta), PepMix™ HCoV-NL63 (Spike Glycoprotein), PepMix™ SARS-CoV-2 (Spike B.1.351 / Beta)
• T Cell Responses against Orthopoxviruses in HIV-Positive Patients
  Stefanie et al., Vaccines (2024)
  Product used: PepMix™ Pan-Poxviridae Select 
• Caveats of chimpanzee ChAdOx1 adenovirus-vectored vaccines to boost anti-SARS-CoV-2 protective immunity in mice
  Cervantes-Torres et al., Applied Microbiology and Biotechnology (2024) - PMID: 38280035
  Product used: PepMix™ SARS-CoV-2 (S-RBD B.1.617.2 / Delta) 
• Comparison of Omicron Breakthrough Infection Versus Monovalent SARS-CoV-2 Intramuscular Booster Reveals Differences in Mucosal and Systemic Humoral Immunity
  Nantel et al., Mucosal Immunology (2024)
  Products used: PepMix™SARS-CoV-2 (Spike P.1 / Gamma), PepMix™ SARS-CoV-2 (Spike B.1.351 / Beta), PepMix™ SARS-CoV-2 (Spike B.1.617.2 / Delta), PepMix™ SARS-CoV-2 (Spike B.1.1.7 / Alpha), PepMix™ SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron) 
• Expanded specific T cells to hypomutated regions of the SARS-CoV-2 using mRNA electroporated antigen presenting cells.
  Ogando-Rivas et al., Methods and Clinical Development (2024)
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2), PepMix™ SARS-CoV-2 (VME1), PepMix™ SARS-CoV-2 (VEMP), PepMix™SARS-CoV-2 (NCAP) 
• Enhanced detection of antigen-specific T cells by a multiplexed AIM assay
  Lemieux et al., Cell Rep Methods (2024) - PMID: 38228152
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein), PepMix™ HIV-1 (GAG) Ultra, PepMix™ HIV-1 (POL) Ultra, PepMix™ HIV-1 (ENV) Ultra, PepMix™ HIV-1 (NEF) Ultra, PepMix™ CMVA (pp65) 
• Three immunizations with Novavax’s protein vaccines increase antibody breadth and provide durable protection from SARSCoV-2
  Lenart et al., Vaccines (2024) - PMID: 38245545
  Products used: PepMix™SARS-CoV-2 (Spike Glycoprotein) 
• Identification of a spike-specific CD8+ T cell epitope following vaccination against the Middle East respiratory syndrome coronavirus in humans
  Harrer et al., Journal of Infectious Diseases (2024) - PMID: 38195212
  Products used: PepMix™ MERS-CoV (Spike Glycoprotein), CEF Pool (extended) 
• Surface-modified measles vaccines encoding oligomeric, prefusion-stabilized SARS-CoV-2 spike glycoproteins boost neutralizing antibody responses to Omicron and historical variants, independent of measles seropositivity
  Muñoz-Alía et al., mBio (2024) - PMID: 38193729
  Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) 
• CD3-downregulation identifies T-helper-cells with superior functionality and distinct metabolism in SARS-CoV2-vaccination- and recall-antigen-specific immunity
  Sattler et al., JCI Insight (2024)
  Products used: PepMix™ SARS-CoV-2 (Spike B.1.1.7 / Alpha), SARS-CoV-2 Antigen Peptide Spike Fusion (SFIEDLLFNKVTLAD) 
• Humoral and cellular immune responses after COVID-19 vaccination of lung transplant recipients and patients on the waiting list: a 6-month follow-up
  Hoek et al., Frontiers in Immunology (2024)
  Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) 
• Protective MVA-ST Vaccination Robustly Activates T Cells and Antibodies in an Aged-Hamster Model for COVID-19
  Clever et al., Vaccines (2024)
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) 
• Optimising a linear ‘Doggybone’ DNA vaccine for influenza virus through the incorporation of DNA targeting sequences and neuraminidase antigen
  Cunliffe et al., Discovery Immunology (2024)'
  Product used: PepMix Influenza A (Neuroamidase /California (H1N1) 
• A quest for universal anti-SARS-CoV-2 T cell assay: systematic review, meta-analysis, and experimental validation
  Binayke et al., NPJ Vaccines (2024) - PMID: 38167915
  Products used: PepMix SARS-CoV-2 (Spike Glycoprotein), PepMix Pan-SARS-CoV-2 Select

2023

• Hepatitis E Virus Epidemiology and Vaccine Response: Studies from Norway and Bangladesh
  Øverbø, Dissertation (2023) 
  Product used: PepMix HEV (ORF2)
• Ineffective control of Epstein-Barr-virus-induced autoimmunity increases the risk for multiple sclerosis
  Vietzen et al., Cell (2023) - PMID: 38091993
  Product used: PepMix™ Collection EBV 
• Evaluation of Luciferase and Prefusion-Stabilized F Protein From Respiratory Syncytial Virus mRNA/LNPs in Pre-Clinical Models Using Jet Delivery Compared to Needle and Syringe
  Meyer et al., Vaccine (2023) 
  Product used: PepMix™ HRSVA (Fusion Glycoprotein F0)
• The immunogenicity and the safety of the adjuvanted glycoprotein E (gE)-based recombinant vaccine against herpes zoster (RZV) in cancer patients during immunotherapy
  Lasagna et al., Human Vaccines & Immunotherapeutics (2023) - PMID: 38037900
  Products used: PepMix VZV (IE63), PepMix VZV (gE)
• Interaction dynamics between innate and adaptive immune cells responding to SARSCoV-2 vaccination in non-human primates
  Schramm et al., Nature Communications (2023) - PMID: 38042809
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• Safety, immunogenicity and efcacy of an mRNA‑based COVID‑19 vaccine, GLB‑COV2‑043, in preclinical animal models
  Lelis et al., Scientific Reports (2023) - PMID: 38040905
  
• Production, purification and immunogenicity of Gag virus-like particles carrying SARS-CoV-2 components
  Gashti et al., Vaccine (2023) - PMID: 38042697
  Product used: PepMix SARS-CoV-2 (NCAP)
• Conjugation of HIV-1 envelope to hepatitis B surface antigen alters vaccine responses in rhesus macaques
  Nettere et al., Vaccines (2023) - PMID: 38001122
  Products used:  PepMix HBV (Large envelope protein), PepMix HIV-1 (ENV) Ultra
• Associations of myeloid cells with cellular and humoral responses following vaccinations in patients with neuroimmunological diseases
  Wang et al., Nature Communications (2023) - PMID: 38007484
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• Impaired Cellular and Antibody immunity after COVID-19 in Chronically Immunosuppressed Transplant Recipients
  Ashokkumar et al., Journal of Surgery and Research (2023)
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB2)
  
• Immunotherapy of cytomegalovirus infection by low-dose adoptive transfer of antiviral CD8 T cells relies on substantial post-transfer expansion of central memory cells but not effector-memory cells
  Holtappels et al., PLoS Pathogens (2023) 
  Product used: custom PepMix
• Hydroxyurea interaction with α7 nicotinic acetylcholine receptor can underlie its therapeutic efficacy upon COVID-19
  Lykhmus et al., Neuroimmunology (2023) - PMID: 38016403
  Product used: custom PepMix
• Concomitant administration of seasonal influenza and COVID-19 mRNA vaccines
  Aydillo et al., Emerging Microbes & Infections (2023) - PMID: 38054302
  Products used: PepMix Influenza A (HA/H1N1/Victoria/2019), Influenza A (HA/H3N2/Darwin/2021), custom PepMix Influenza B Nucleoprotein
• A Phase I/II Clinical Trial of Intradermal, Controllable Self-Replicating Ribonucleic Acid Vaccine EXG-5003 against SARS-CoV-2
  Koseki et al., Vaccines (2023) 
  Product used: PepMix SARS-CoV-2 (S-RBD)
• Efectiveness ofVSV vectored SARS‑CoV‑2 spike when administered through intranasal, intramuscular or a combination of both
  Beitari et al., Scientific Reports (2023) - PMID: 38049498
  Products used: PepMix SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• Tiza–Titre increase and enhanced immunity through an adjuvanted, recombinant herpes zoster subunit vaccine in patients with liver cirrhosis and post-liver transplantation: a study protocol for a prospective cohort study
  Vollmer-Raschdorf et al., BMJ Open (2023) 
  Product used: PepMix VZV (gE)
• Caracterización del agotamiento de los linfocitos T en pacientes con síndrome Long COVID
  Benéitez, Thesis (2023) 
  Products used: PepMix Influenza A (HA/California (H1N1)), custom PepMix Influenza (HA/Perth (H3N2))
• Cytomegalovirus-specific T cell immunity reconstitution following allogeneic hematopoietic stem cell transplantation: a pilot study
  Wang et al., Research Square (2023) 
  Products used: PepMix CMVA (IE-1), PepMix CMVA (pp65)
• Immunogenicity of a silica nanoparticle-based SARS-CoV-2 vaccine in mice
  Barbey et al., European Journal of Pharmaceutics and Biopharmaceutics (2023) - PMID: 37774890
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• Impaired immune responses and prolonged viral replication in lung allograft recipients infected with SARS‑CoV‑2 in the early phase after transplantation
  Glueck et al., Infection (2023) - PMID: 37922037
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• Early humoral and cellular responses after bivalent SARS‐CoV‐2 mRNA‐1273.214 vaccination in long‐term care and retirement home residents in Ontario, Canada: An observational cohort study
  Breznik et al., Journal of Medical Virology (2023) - PMID: 37822054
  Product used: PepMix SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron)
• Cytomegalovirus-Specific T Cells in Pediatric Liver Transplant Recipients
  Getsuwan et al., Viruses (2023) 
  Products used: PepMix CMVA (IE-1), PepMix CMVA (pp65)
• Humoral and Cellular Immunity Are Significantly Affected in Renal Transplant Recipients, Following Vaccination with BNT162b2
  Fylaktou et al., Vaccines (2023) 
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• Structural surfaceomics reveals an AML-specific conformation of integrin β2 as a CAR T cellular therapy target
  Mandal et al., Nature Cancer (2023) 
  Products used: PepMix EBV (LMP1), PepMix EBV (EBNA1), PepMix EBV (LMP2), PepMix EBV (BZLF1), PepMix EBV (BRLF1), PepMix CMVA (pp65), PepMix CMVA (IE-1)
• SARS-CoV-2 infection establishes a stable and age-independent CD8+ T cell response against a dominant nucleocapsid epitope using restricted T cell receptors
  Choy et al., Nature Communications (2023) - PMID: 37872153
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1)
• Revaccination of patients with systemic lupus erythematosus or rheumatoid arthritis without an initial COVID-19 vaccine response elicits seroconversion in half of the patients
  Ammitzbøll et al., Clinical and Experimental Rheumatology (2023) - PMID: 37877429
  
• An interferon-integrated mucosal vaccine provides pan-sarbecovirus protection in small animal models
  Yuen et al., Nature Communications (2023) - PMID: 37875475
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• Dendritic Cell-Mediated Cross-Priming by a Bispecific Neutralizing Antibody Boosts Cytotoxic T Cell Responses and Protects Mice against SARS-CoV-2
  Lázaro-Gorines et al., Advanced Science (2023) 
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• Immunology of THymectomy And childhood CArdiac transplant (ITHACA): protocol for a UK-wide prospective observational cohort study to identify immunological risk factors of post-transplant lymphoproliferative disease (PTLD) in thymectomised children
  Offor et al., BMJ Open (2023) - PMID: 37865406
  Products used: custom PepMix
• T regulatory lymphocytes specific for SARS-CoV-2 display increased functional plasticity
  Esparcia-Pinedo et al., Clinical Immunology - PMID: 37827267
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2), PepMix™ CMVA (pp65)
• Immune Profile Determines Response to Vaccination against COVID-19 in Kidney Transplant Recipients
  Stai et al., Vaccines (2023) - PMID: 37896986
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• Cytokine profile of anti-spike CD4+T cells predicts humoral and CD8+T cell responses after anti-SARSCoV-2 mRNA vaccination
  Tartour et al., Research Square (2023) - PMID
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• Pretransplant BKV-IgG serostatus and BKV-specific ELISPOT assays to predict BKV infection after kidney transplantation
  Bae et al., Frontiers in Immunology (2023) - PMID: 37809095
  Products used: PepMix BKV (capsid protein VP1), PepMix BKV (capsid protein VP2), PepMix BKV (capsid protein VP2, isoform VP3)
• An RNA-Scaffold Protein Subunit Vaccine for Nasal Immunization
  Lam et al., Vaccines (2023) - PMID: 37896953
  Product used: PepMix SARS-CoV-2 (S-RBD)
• Selection of cross-reactive T cells by commensal and food-derived yeasts drives cytotoxic TH1 cell responses in Crohn’s disease
  Martini et al., Nature Medicine (2023) - PMID: 37749331
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• Preexisting Enhancing Antibodies in Vaccinated Participants Accelerate Dengue Virus 1 Infection Following Live Virus Human Challenge
  Lyke et al., Research Square (2023)  
  Product used: Custom PepMix
• Enhanced Omicron subvariant cross-neutralization efficacy of a SARS-CoV-2 BA.4/5 mRNA vaccine encoding a noncleaved, nonfusogenic spike antigen
  Oh et al., Research Square (2023) 
  Product used: PepMix SARS-CoV-2 (Spike B.1.1.529 / BA.4 & BA.5 / Omicron)
• Spontaneous HIV expression during suppressive ART is associated with the magnitude and function of HIVspecific CD4+ and CD8+ T cells
  Dubé et al., Cell Hosts Microbe (2023) - PMID: 37708853
  Products used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• Responses of patients with cancer to mRNA vaccines depend on the time interval between vaccination and last treatment
  Donhauser et al., Journal for ImmunoTherapy of Cancer - PMID: 37730271
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• Long-term humoral and cellular immunity after primary SARS-CoV-2 infection: A 20- month longitudinal study
  Hvidt et al., Research Square (2023) - PMID: 37974069
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• SARS-CoV-2 variants of concern elicit divergent early immune responses in hACE2 transgenic mice
  Fricke et al., European Journal of Immunology (2023) - PMID: 37609807
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• A cell-free antigen processing system informs HIV-1 epitope selection and vaccine design
  Sengupta et al., Journal of Experimental Medicine (2023) - PMID: 37058141
  Products used: PepMix HIV-1 (NEF) Ultra, HIV-1 (Con B gag motif)
• Lymph node dendritic cells harbor inducible replication-competent HIV despite years of suppressive ART
  Banga et al., Cell Host & Microbe (2023) - PMID: 37751747
  
• Ablative radiation alone in stage I lung cancer produces an adaptive systemic immune response: insights from a prospective study
  Voong et al., Journal for ImmunoTherapy of Cancer (2023) 
  Products used: CEFX Ultra SuperStim Pool MHC-II Subset & PepMix™ HIV-1 (GAG) Ultra
• Enhancing Anti-SARS-CoV-2 Neutralizing Immunity by Genetic Delivery of Enveloped Virus-like Particles Displaying SARS-CoV-2 Spikes
  Yang et al., Vaccines (2023) 
  Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• Early Omicron infection is associated with increased reinfection risk in older adults in long-term care and retirement facilities
  Breznik et al., The Lancet (2023)
  Product used: PepMix SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron)
• First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial
  Thibaudin et al., Nature Medicine (2023) - PMID: 37563240
  Products used: PepMix Human (NY-ESO-1)
• Intradermal administration of DNA vaccine targeting Omicron SARS‑CoV‑2 via pyro‑drive jet injector provides the prolonged neutralizing antibody production via germinal center reaction
  Hayashi et al., Scientific Reports (2023) - PMID: 37563266
  Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2), SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron)
• Lymph node targeted multi-epitope subunit vaccine promotes effective immunity to EBV in HLA-expressing mice
  Dasari et al., Nature Communications (2023) - PMID: 37553346
  Products used: PepMix EBV (GP350/GP340)
• Safety and immunogenicity of a SARS-CoV-2 Gamma variant RBD-based protein adjuvanted vaccine used as booster in healthy adults
  Pasquevich et al., Nature Communications (2023) 
  Product used: PepMix SARS-CoV-2 (S-RBD P.1 / Gamma)
• Zika virus infection during pregnancy and vertical transmission: case reports and peptide-specic cellmediated immune responses
  Soudeyns et al., Research Sqaure (2023) 
  Products used: PepMix CMVA (pp65), ZIKV (NS1) Ultra, ZIKV (C) Ultra, ZIKV (E) Ultra
• YF17D-vectored Ebola vaccine candidate protects mice against lethal surrogate Ebola and yellow fever virus challenge
  Lemmens et al., Vaccines (2023) 
  Product used: PepMix Zaire Ebola (GP/Kikwit-95)
• Breadth and Durability of SARS-CoV-2-Specific T Cell Responses following Long-Term Recovery from COVID-19
  Dang et al., Microbiology Spectrum (2023) - PMID: 37428088
  Products used: PepMix SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (NCAP), SARS-CoV-2 (VEMP), SARS-CoV-2 (VME1), SARS-CoV-2 (ORF10), SARS-CoV-2 (ORF9B)
  Custom PepMix : SARS-CoV-2 ORF3a, ORF6, ORF7a, ORF7b, ORF8
• A localizing nanocarrier formulation enables multi-target immune responses to multivalent replicating RNA with limited systemic inflammation
  Kimura et al., Molecular Therapy (2023) - PMID: 37403357
  Product used: PepMix™ SARS-CoV-2 (Spike B.1.351 / Beta)
• Unmodified rabies mRNA vaccine elicits high cross-neutralizing antibody titers and diverse B cell memory responses
  Hellgren et al., Nature Communications (2023) - PMID: 37349310
  Product used: PepMix Rabies virus (Glycoprotein)
• Immunological imprinting of humoral immunity to SARS-CoV-2 in children
  Dowell et al., Nature Communications - PMID: 37386081
  Product used: PepMix™ SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron) & Influenza A (MP1 (H3N2))
• Adjuvant lipidoid-substituted lipid nanoparticles augment the immunogenicity of SARS-CoV-2 mRNA vaccines
  Han et al., Nature Nanotechnology (2023) - PMID: 37365276
  Products used: PepMix™ SARS-CoV-2 (S-RBD)
• Characterization of T cell responses to SARS-CoV-2 following infection and vaccination
  Law, Dissertation (2023)
  Products used: PepMix™SARS-CoV-2 (VME1), SARS-CoV-2 (VEMP), SARS-CoV-2 (NCAP) & SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• Oligosymptomatic long-term carriers of SARS-CoV-2 display impaired innate resistance but increased high-affinity anti-Spike antibodies
  Montes-Cobos et al., iScience (2023) 
  Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
• Early evaluation of the safety, reactogenicity, and immune response after a single dose of modified vaccinia Ankara–Bavaria Nordic vaccine against mpox in children: a national outbreak response
  Ladhani et al., The Lancet (2023) - PMID: 37336224
  Product used: Custom PepMix
• Third and Fourth Vaccine Doses Broaden and Prolong Immunity to SARSCoV-2 in Adult Patients with Immune-Mediated Inammatory Diseases
  Cheung et al., Journal of Immunology (2023) - PMID: 37326480
  Product used: PepMix SARS-CoV-2 (Spike B.1.1.529 / BA.4 & BA.5 / Omicron)
• T-Cell-Dominated Immune Response Resolves Protracted SARS-CoV-2 Infection in the Absence of Neutralizing Antibodies in an Immunocompromised Individual
  Bunse et al., Microorganisms (2023) - PMID: 37375064
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• Engineered tumor-specific T cells using immunostimulatory photothermal nanoparticles
  Sweeney et al., Cytotherapy (2023) - PMID: 37278683
  Products used: custom PepMix
• High efficacy of VLA2001 vaccine against SARSCoV-2 infection in non-human primates
  Le Grand et al., Research Square (2023) 
  Products used: PepMix™ SARS-CoV-2 (S-RBD) & SARS-CoV-2 (NCAP)
• A novel multi-antigenic parapoxvirus-based vaccine demonstrates efficacy in protecting hamsters and non-human primates against SARS-CoV-2 challenge
  Reguzova et al., Research Square et al., (2023) 
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) & SARS-CoV-2 (NCAP)
• The Influence of Adjuvant Type on the Immunogenicity of RBD/N Cocktail Antigens as a Vaccine Candidate against SARS-CoV-2 Virus
  Brzuska et al., Microbiology Spectrum (2023) - PMID: 37199661
  Product used: PepMix™ SARS-CoV-2 (S-RBD)
• The effects of exercise training for eight weeks on immune cell characteristics among breast cancer survivors
  Echarri et al., Frontiers Sports Act. Living (2023) - PMID: 37252426
  Product used: PepMix™ CMVA (pp65) & VZV (IE63)
• Specific immune response to mRNA vaccines against COVID-19 in patients receiving allogeneic stem cell transplantation for myeloid malignancy was altered by immunosuppressive therapy
  Macková et al., Leukemia Research (2023) - PMID: 37216792
  Product used: PepMix™ SARS-CoV-2 (NCAP)
• Robust Vaccine-Induced as Well as Hybrid B- and T-Cell Immunity across SARS-CoV-2 Vaccine Platforms in Peoplen with HIV
  Verburgh et al., Microbiology Spectrum (2023) - PMID: 37166335
  Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) & SARS-CoV-2 (NCAP)
• A protective, single-visit TB vaccination regimen by co-administration of a subunit vaccine with BCG
  Dijkman et al., Vaccines (2023) - PMID: 37160970
  Product used: PepMix M. tuberculosis (ESAT-6), M. tuberculosis (PPE68), M. tuberculosis (EspA), PepMix M. tuberculosis (MPT64) & custom PepMix (for EspI, EspC, MPT70, MPT83), 
• Pre-pandemic SARS-CoV-2-specific IFN-γ and antibody responses were low in Ugandan samples and significantly reduced in HIV-positive specimens
  Nantambi et al., Frontiers in Immunology (2023) - PMID: 37153598
  Product used: PepMix™ SARS-CoV-2 (Spike Glycoproteins)
• High-dimensional analysis of 16 SARS-CoV-2 vaccine combinations reveals lymphocyte signatures correlating with immunogenicity
  Nuñez et al., Nature Immunology (2023) - PMID: 37095378
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) & SARS-CoV-2 (NCAP)
• Impact of age and comorbidities on SARS-CoV-2 vaccine-induced T cell immunity
  Dietz et al., Communications Medicine (2023) - PMID: 37095240
  Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
• ESCRT recruitment to SARS-CoV-2 spike induces virus-like particles that improve mRNA vaccines
  Hoffmann et al., Cell (2023) - PMID: 37146611
  Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
• COVID-19 relapse associated with SARS-CoV-2 evasion from CD4+ T-cell recognition in an agammaglobulinemia patient
  Morita et al., iScience (2023) - PMID: 37124420
  Products used: 27 structural and non-structural PepMix SARS-CoV-2 proteins
• Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapy
  Sharma et al., Journal for Immunotherapy of Cancer (2023) - PMID: 37072346
  Product used: PepMix™ EBV (EBNA1), EBV (LMP1), EBV (LMP2) & EBV (BARF1)
• Exercise mobilizes diverse antigen specific T-cells and elevates neutralizing antibodies in humans with natural immunity to SARS CoV-2
  Baker et al., Brain, Behaviour & Immunity (2023) - PMID:  36743994
  Products used: PepMix™ Human (Actin) & SARS-CoV-2 (Spike Glycoprotein)
• A cell-free antigen processing system informs HIV-1 epitope selection and vaccine design
  Sengupta et al., Journal of Experimental Medicine (2023) - PMID: 37058141
  Product used: PepMix™ HIV-1 (NEF) Ultra & HIV-1 (Con B gag motif)
• Long-Term Follow-Up after Adoptive Transfer of BK-Virus-Specific T Cells in Hematopoietic Stem Cell Transplant Recipients
  Koldehoff  et al., Vaccines (2023) - PMID: 37112757
  Product used: PepMix™ BKV (capsid protein VP1) & BKV (large T antigen)
• Metabolic interventions improve HBV envelope-specific T-cell responses in patients with chronic hepatitis B
  Fu et al., Hepatology International (2023) - PMID: 36976426
  Product used: PepMix™ HBV (Capsid Protein) Ultra & HBV (LEP) Ultra
• Omicron BA.4/5 neutralization and T-cell responses in organ transplant recipients after Booster mrna vaccine: a Multicenter Cohort Study
  Ferreira et al., Clinical Infectious Diseases (2023) - PMID: 36975097
  Product used: PepMix SARS-CoV-2 (Spike B.1.1.529 / BA.4 & BA.5 / Omicron)
• Cytotoxic T Cells Targeting Spike Glycoprotein Are Associated with Hybrid Immunity to SARS-CoV-2
  Phan et al., Journal of Immunology (2023) - PMID: 36961450
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) & SARS-CoV-2 (NCAP)
• Combination Ad26.RSV.preF/preF protein vaccine induces superior protective immunity compared with individual vaccine components in preclinical models
  Saeland et al., Vaccines (2023) - PMID: 36949051
  Product used: PepMix HRSVA (Fusion Glycoprotein F0)
• Humoral and cellular immunity to SARS-CoV-2 after vaccination with mRNA vaccines in PLWH with discordant immune response. Influence on the vaccine administered
  López-Cortés et al., Frontiers in Immunology (2023) - PMID: 37006309
  Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
  
• SARS-CoV-2 spike-ferritin-nanoparticle adjuvanted with ALFQ induces long-lived plasma cells and cross-neutralizing antibodies
  Shrivastava et al., Vaccines (2023) - PMID: 36934088
  Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
• Immunogenicity of COVID-eVax Delivered by Electroporation Is Moderately Impacted by Temperature and Molecular Isoforms
  D'Alessio et al., Vaccines (2023) - PMID: 36992261
  Product used: PepMix™ SARS-CoV-2 (S-RBD)
• Spezifische T-Zellantwort und Immunevasion beim humanen Herpesvirus 6 und SARS-CoV-2
  Hollaus, Dissertation (2023)
• Engineering potent live attenuated coronavirus vaccines by targeted inactivation of the immune evasive viral deubiquitinase
  Myeni et al., Nature Communications (2023) 
  Product used: PepMix MERS-CoV (Spike Glycoprotein)
• Schistosoma mansoni infection alters the host pre-vaccination environment resulting in blunted Hepatitis B vaccination immune responses.
  Muir et al., MedRxiv (2023) 
  Product used: PepMix HBV (Large envelope protein)
• A systems immunology study comparing innate and adaptive immune responses in adults to COVID-19 mRNA and adenovirus vectored vaccines
  Ryan et al., Cell Reports Medicine (2023) 
  Product used: PepMix Chimpanzee Adenovirus Y25 (Hexon Protein)
• Incorporation of SARS-CoV-2 spike NTD to RBD Protein Vaccine Improves Immunity Against Viral Variants
  Montgomerie et al., IScience (2023) 
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• Pyrimidine de novo synthesis inhibition selectively blocks effector but not memory T cell development
  Scherer et al., Nature Immunology (2023) 
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• Carbohydrate fatty acid monosulphate: oil-in-water adjuvant enhances SARS-CoV-2 RBD nanoparticle-induced immunogenicity and protection in mice
  Nanishi et al., Vaccines (2023) 
  Product used: PepMix SARS-CoV-2 (S-RBD)
• Efficacy of an unmodified bivalent mRNA vaccine against SARS-CoV-2 variants in female small animal models
  Corleis et al., Nature Communications (2023) 
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• The role of the T-cell mediated immune response to Cytomegalovirus infection in intrauterine transmission
  Soriano-Ramos et al., PLOS One (2023) 
  Products used: PepMix CMVA (IE-1) & CMVA (pp65)
• Multimodal single‑cell analyses of peripheral blood mononuclear cells of COVID‑19 patients in Japan
  Kashima et al., Scientific Reports (2023) - PMID: 36732528
  Products used: PepMix SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (NCAP), SARS-CoV-2 (VEMP), SARS-CoV-2 (VME1), ....ORF3a/6/7a/7b/8/9b/10
• Trimeric, APC-Targeted Subunit Vaccines Protect Mice against Seasonal and Pandemic Influenza
  Tjärnhage et al., Journal of Virology (2023) 
  Products used: PepMix Influenza A (HA/Puerto Rico/8/1934 H1N1) & Influenza A (HA /California (H1N1))
• Anti-SARS-CoV-2 cellular response after 2 and 3 doses of BNT162b2 mRNA vaccine in lymphoma patients receiving anti-CD20 antibodies
  Gressens et al., Vaccines (2023) 
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• Long COVID manifests with T cell dysregulation, inflammation, and an uncoordinated adaptive immune response to SARS-CoV-2
  Yin et al., BioRxiv (2023) 
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• Exercise mobilizes diverse antigen specific T-cells and elevates neutralizing antibodies in humans with natural immunity to SARS CoV-2
  Baker et al., Brain Behaviour & Immunity - Health (2023) 
  Products used: PepMix Human (Actin) & SARS-CoV-2 (Spike Glycoprotein)
• The HDAC inhibitor zabadinostat is a systemic regulator of adaptive immunity
  Liu et al., Communications Biology (2023)
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• SARS-CoV-2 Omicron BA.4/BA.5 Mutations in Spike Leading to T Cell Escape in Recently Vaccinated Individuals
  Emmelot et al., Viruses (2023)
• Immunogenicity and safety of a two-dose regimen with hepatitis E virus vaccine in healthy adults in rural Bangladesh: A randomized, double-blind, controlled, phase 2/pilot trial
  Øverbø et al., Vaccine (2023) 
  Product used: PepMix HEV (ORF2)
• A linear DNA encoding the SARS-CoV-2 receptor binding domain elicits potent immune response and neutralizing antibodies in domestic cats
  Conforti et al., Molecular Therapy (2023) 
  Product used: PepMix SARS-CoV-2 (S-RBD)
• Immunogenicity and safety of Biological E’s CORBEVAX™ vaccine as a heterologous booster dose in adult volunteers previously vaccinated with two doses of either COVISHIELD™ or COVAXIN: A Prospective double-blind randomised hase III clinical study
  Thuluva et al., MedRxiv (2023)
  Product used: PepMix SARS-CoV-2 (S-RBD)
• The prospect of universal coronavirus immunity: a characterization of reciprocal and non-reciprocal T cell responses against SARS-CoV2 and common human coronaviruses
  Soni et al., BioRxiv (2023)
• Assessment of Immunogenicity and Efficacy of CV0501 mRNA-based Omicron COVID-19 Vaccination in Small Animal Models
  Roth et al., BioRxiv (2023)
  Product used: PepMix SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron)
• Diminished responses to mRNA-based SARS-CoV-2 vaccines in individuals with rheumatoid arthritis on immune modifying therapies
  Klebanoff et al., MedRxiv (2023) 
  Products used: CEFX Ultra SuperStim Pool, PepMix SARS-CoV-2 (Spike Glycoprotein)
• An inactivated SARS-CoV-2 vaccine induced cross-neutralising persisting antibodies and protected upon challenge in small animals
  Offersgaard et al., iScience (2023)
  Products used: SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (S-RBD), SARS-CoV-2 (NCAP), SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• Safety, tolerability, and immunogenicity of a new SARS-CoV-2 recombinant Gamma variant RBD-based protein adjuvanted vaccine, used as heterologous booster in healthy adults: a Phase 1 interim report
  Pasquevich et al., MedRxiv (2023)
  Product used: PepMix SARS-CoV-2 (S-RBD P.1 / Gamma)
• Single-dose YF17D-vectored Ebola vaccine candidate protects mice against both lethal surrogate Ebola and yellow fever virus challenge
  Lemmens et al., BioRxiv (2023)
  Products used: PepMix Zaire Ebola (GP/Kikwit-95), Yellow fever (NS4B)

Archive

• Persistence of SARS-CoV-2 neutralizing antibodies and anti-Omicron IgG induced by BNT162b2 mRNA vaccine in patients with autoimmune inflammatory rheumatic disease: An explanatory study in Japan
  Yamaguchi et al., The Lancet (2023) 
  Product used: PepMix SARS-CoV-2 (Spike), SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron)
• Potent high-avidity neutralizing antibodies and T cell responses after COVID-19 vaccination in individuals with B cell lymphoma and multiple myeloma
  Keppler-Hafkemeyer et al., Nature Cancer (2023) - PMID: 36543907
  Products used: PepMix SARS-CoV-2 (Spike B.1.617.2 / Delta), Human Adenovirus 5 (Hexon Protein), HCoV-OC43 (Spike Glycoprotein), SARS-CoV-2 (NCAP)
• Listeria-vectored multi-antigenic tuberculosis vaccine protects C57BL/6 and BALB/c mice and guinea pigs against Mycobacterium tuberculosis challenge
  Jia et al., Communications Biology (2022) 
  Products used: PepMix M. tuberculosis (Ag85B), M. tuberculosis (EspA), M. tuberculosis (EsxN), M. tuberculosis (TB8.4), M. tuberculosis (MPT64), custom PepMix (EsxH, EsxB, EsxA, ppe68)
• A novel intradermal tattoo-based injection device enhances the immunogenicity of plasmid DNA vaccines
  Gomez et al., Vaccines (2022) - PMID: 36543794
  Products used: PepMix Zaire Ebola (GP/Mayinga-76)
• Longitudinal adaptive immune responses following sequential SARS-CoV-2 vaccinations in MS patients on anti-CD20 therapies and sphingosine-1-phosphate receptor modulators
  Sabatino et al., Multiple Sclerosis and Related Disorders (2022) 
  Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• Comprehensive Analysis of Epstein-BarrVirus LMP2A-Specific CD8+ and CD4+ T Cell Responses Restricted to Each HLA Class I and II Allotype Within an Individual
  Jo et al., Immune Network (2022) 
  Product used: PepMix EBV (LMP2)
• Accelerated waning of immune responses to a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases
  Mrak et al., Journal of Autoimmunity (2022) 
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron)
• Characterization of Three Variants of SARS-CoV-2 In Vivo Shows Host-Dependent Pathogenicity in Hamsters, While Not in K18-hACE2 Mice
  Toomer et al., Viruses (2022) - PMID: 36423193
• Product used: PepMix SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron)
• High antibody levels and reduced cellular response in children up to one year after SARS-CoV-2 infection
  Jacobsen et al., Nature Communications (2022) 
  Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• Allogeneic, Off-the-Shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high risk patients
  Vasileiou et al., Haemtologica (2022) 
  Products used: PepMix SARS-CoV-2 (NCAP), SARS-CoV-2 (VME1), SARS-CoV-2 (VEMP), SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (NS7A), SARS-CoV-2 (NS7B), SARS-CoV-2 (NS8)
• SARS-CoV-2-Spike Antibody and T-Cell Responses Elicited by a Homologous Third mRNA COVID-19 Dose in Hemodialysis and Kidney Transplant Recipients
  Panizo et al., Microorganisms (2022) 
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• Combined plasma cell-free DNA detection and IFNγ/TNF-α dual fluorospot assays for diagnosing active tuberculosis
  Kim et al., Research Square (2022)
  Products used: PepMix M. tuberculosis (ESAT-6), M. tuberculosis (CFP-10), M. tuberculosis (Ag85B)
• Four-Parameter FluoroSpot Assay Reveals That the Varicella Zoster Virus Elicits a Robust Memory T Cell IL-10 Response throughout Childhood
  Nilsson et al., Journal of Virology (2022) - PMID: 36314824
  Products used: PepMix VZV (IE63) & VZV (gE)
• Characterization of B-cell and T-cell responses to a tetravalent dengue purified inactivated vaccine in healthy adults
  Friberg et al., Vaccines (2022) - PMID: 36316335
  Product used: PepMix Dengue 1 (E) Ultra
• Reduced humoral but stable cellular SARS-CoV-2-specific immunity in liver transplant recipients in the first year after COVID-19
  Kirchner et al., PLoS One (2022) - PMID: 36322587
  Products used: PepMix Pan-SARS-CoV-2 Select, SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2), SARS-CoV-2 (NCAP), SARS-CoV-2 (VEMP), HCoV-229E (Spike Glycoprotein), HCoV-OC43 (Spike Glycoprotein), HRSVB (Nucleocapsid Protein N), Influenza A (M1) Ultra
• Efficacy of mucosal vaccination using a protozoan parasite as a vehicle for antigen delivery: IgG and neutralizing response after rectal administration of LeCoVax-2, a candidate vaccine against COVID-19
  Epis et al., Pharmacological Research (2022) - PMID: 36336215
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• Immunological signature in human cases of monkeypox infection in 2022 outbreak: an observational study
  Agrati et al., The Lancet (2022)
  Products used: PepMix Vaccinia virus (MVA105L), Vaccinia virus (MVA074R), Vaccinia virus (MVA121L)
• SARS-CoV-2 Spike-specific IFN-gamma T-cell Response After COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant
  Imhof et al., Infectious Disease (2022) 
  Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• Chimeric mRNA based COVID-19 vaccine induces protective immunity against Omicron and Delta variants
  Hu et al., Molecular Therapy (2022) 
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• Humoral and Cellular Responses to a Delayed Fourth SARS-CoV-2 mRNA-Based Vaccine in Weak Responders to 3 Doses Kidney Transplant Recipients
  Del Bello et al., Vaccines (2022) - PMID: 36146517
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• A third dose of the unmodified COVID-19 mRNA vaccine CVnCoV enhances quality and quantity of immune responses
  Lenart et al., Molecular Therapy (2022) 
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• A Tale Of T ale Of Two Transgenes: Aa ansgenes: Aav-Dystr v-Dystrophin And Aa ophin And Aav-Spike Reveal Common Themes For Gene Therapy And Vaccines
  Greer, Dissertation (2022) 
  Products used: PepMix SARS-CoV-2 (Spike Glycoprotein) and SARS-CoV-2 (Spike B.1.1.7 / Alpha)
• Immunogenicity of SARS-CoV-2 spike antigens derived from Beta & Delta variants of concern
  Akache et al., Vaccines (2022) 
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• Artificial Cell Membrane Polymersome-Based Intranasal Beta Spike Formulation as a Second Generation Covid-19 Vaccine
  Lam et al., ACS Nano (2022) -
  Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• Signs of immunosenescence correlate with poor outcome of mRNA COVID-19 vaccination in older adults
  Palacios-Pedrero et al., Nature Aging (2022) 
  Product used: PepMix SARS-CoV-2 (NCAP)
• Rekombinowane cząstki wirusopodobne jako potencjalne antygeny szczepionkowe przeciwko wirusowi Zika
  Brzuska, Dissertation (2022)
  Products used: PepMix ZIKV (E) Ultra and ZIKV (M) Ultra
• Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial
  Gunst et al., Nature Medicine (2022) - PMID: 36253609
  Product used: PepMix HIV Gag Ultra
• NVX-CoV2373-induced cellular and humoral immunity towards parental SARS-CoV-2 and VOCs compared to BNT162b2 and mRNA-1273-regimens
  Hielscher et al., Journal of Clinical Virology (2022) - PMID: 36279695
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• Immune Response after the Fourth Dose of SARS-CoV-2 mRNA Vaccine Compared to Natural Infection in Three Doses’ Vaccinated Solid Organ Transplant Recipients
  Busà et al., Vaccines (2022) - PMID: 36298854
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (NCAP) and CEFX Ultra SuperStim Pool
• Proinflammatory Innate Cytokines and Distinct Metabolomic Signatures Shape the T Cell Response in Active COVID-19
  Binayke et al., Vaccines (2022) - PMID: 36298628
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose
  Belik et al., Research Square (2022) 
  Products used: PepMix SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron), and SARS-CoV-2 (Spike B.1.1.529 / BA.2 / Omicron)
• Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8+ T cell immunity
  Rosás-Umbert et al., Nature Communications (2022)
  Products used: PepMix HIV-1 (GAG) Ultra, HIV-1 (ENV) Ultra, HIV-1 (NEF) Ultra, HIV-1 (POL) Ultra
• Ablation of CD8+ T cell recognition of an immunodominant epitope in SARS-CoV-2 Omicron variants BA.1, BA.2 and BA.3
  Swaminathan et al., Nature Communications 
  Products used: PepMix SARS-CoV-2 (NCAP), SARS-CoV-2 (NS6), SARS-CoV-2 (NS7A), SARS-CoV-2 (NS7B), SARS-CoV-2 (NS8), SARS-CoV-2 (ORF9B), SARS-CoV-2 (ORF10), SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (VEMP), SARS-CoV-2 (VME1), SARS-CoV-2 (Y14)
• Accumulation of mutations in antibody and CD8 T cell epitopes in a B cell depleted lymphoma patient with chronic SARS-CoV-2 infection
  Khatamzas et al., Nature Communication (2022)
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• Evidence of premature lymphocyte aging in people with low anti-spike antibody levels after BNT162b2 vaccination
  Huang et al., iScience (2022) - PMID: 
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• SARS-CoV-2-specicific humoral immunity in convalescent patients with mild COVID-19 is supported by CD4+ T-cell help and negatively correlated with Alphacoronavirus-specific antibody titer
  Odendahl et al., Immunology Letters (2022) 
  Product used: PepMix CMVA (pp65)
• Comparison of the Immune Responses to COVID-19 Vaccines in Bangladeshi Population
  Sarker et al., Vaccines (2022) 
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• Comparison between enzyme‐linked immunospot assay and intracellular cytokine flow cytometry assays for the evaluation of T cell response to SARS‐CoV‐2 after symptomatic COVID‐19
  Villemonteix et al., Immunity, Inflammation and Disease (2022) - PMID
  PepMix SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (NCAP)
  
• Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models
  Hajnik et al., Science Translational medicine (2022) - PMID: 36103514
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
  
• A Recombinant VSV-Based Bivalent Vaccine Effectively Protects against Both SARS-CoV-2 and Influenza A Virus Infection
  Ao et al., Journal of Virology (2022) - PMID: 36069551
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1)
• SARS-CoV-2 mRNA-vaccine candidate; COReNAPCIN, induces robust humoral and cellular immunity in mice and non-human primates
  Alimohammadi et al., Vaccines (2022) - PMID: 36056015
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• SARS‑CoV‑2‑reactive IFN‑γ‑producing CD4+ and CD8+T cells in blood do not correlate with clinical severity in unvaccinated critically ill COVID‑19 patients
  Olea et al., Scientific Reports (2022) - PMID: 35995830
• Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response
  Stort et al., Oncoimmunology (2022) 
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• Humoral and cellular responses to mRNA-based COVID-19 booster vaccinations in patients with solid neoplasms under active treatment
  Su et al., ESMO Open (2022)
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• Protective Immunity of COVID-19 Vaccination with ChAdOx1 nCoV-19 Following Previous SARS-CoV-2 Infection: A Humoral and Cellular Investigation
  Azamor et al., Viruses (2022) - PMID: 36146723
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• Antibody and T-cellular response to COVID-19 booster vaccine in SARS-CoV-1 survivors
  Lu et al., Clinical Immunology (2022) 
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
  
• Immunogenicity and safety of a fourth COVID-19 vaccination in rituximab-treated patients: an openlabel extension study
  Mrak et al., Annals of Rheumatic Disease (2022) - PMID: 35977809
• Gene Transfer in Adeno-Associated Virus Seropositive Rhesus Macaques Following Rapamycin Treatment and Subcutaneous Delivery of AAV6, but Not Retargeted AAV6 Vectors
  Stone et al., Human Gene Therapy (2022)
• SARS-CoV-2-specific CD4+ T cell longevity correlates with Th17-like phenotype
  Terahara et al., iScience (2022) - PMID: 35992306
• Japanese encephalitis virus infection in its natural amplification and reservoir host, the pig
  Redant, Dissertation (2022) 
• Secreted heat shock protein gp96-Ig and OX40L-Fc combination vaccine enhances SARS-CoV-2 Spike (S) protein-specific B and T cell immune responses
  Padula et al., Vaccine: X (2022) - PMID: 35936992
  Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SU1 & SU2)
• Analysis of the Specific Immune Response after the Third Dose of mRNA COVID-19 Vaccines in Organ Transplant Recipients: Possible Spike-S1 Reactive IgA Signature in Protection from SARS-CoV-2 Infection
  Miele et al., Microorganisms (2022)
  Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SU1 & SU2) & SARS-CoV-2 NCAP
  
• mRNA booster vaccination protects aged mice against the SARS-CoV-2 Omicron variant
  Nanishi et al., Communications Biology (2022) 
• Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose
  Renia et al., Nature Communications
• The long term vaccine-induced anti-SARS-CoV-2 immune response is impaired in quantity and qualityunder TNFα blockade
  Geisen et al.,  Journal of Medical Virology (2022) - PMID: 35945627
• Clinical outcomes, immunogenicity, and safety of BNT162b22 Vaccine in Primary Antibody Deficiency
  Milota et al., Authorea (2022) 
  
• DNA-Vaccine-Induced Immune Response Correlates with Lower Viral SARS-CoV-2 Titers in a Ferret Model
  Compagnone et al., Vaccines (2022) - PMID: 35893826
• SARS-CoV-2 Vaccine-Induced Antibody and T-Cell Response in SARS-CoV-1 Survivors
  Duan et al., Cell Reports (2022) 
  
• Comparative immunogenicity and reactogenicity of heterologous ChAdOx1-nCoV-19-priming and BNT162b2 or mRNA1273-boosting with homologous COVID-19 vaccine regimens
  Klemis et al., Nature Communications (2022) 
• Brief Research Report: Anti-SARS-CoV-2 Immunity in Long Lasting Responders to Cancer Immunotherapy Through mRNA-Based COVID-19 Vaccination
  Sistere-Oro et al., Frontiers in Immunology (2022) 
  
• Analysis of the humoral and cellular response after the third COVID-19 vaccination in patients with autoimmune hepatitis
  Hartl et al., Liver International (2022) - PMID: 35840342
• Respiratory mucosal immunity against SARS-CoV-2 following mRNA vaccination
  Tang et al., Science Immunology (202) - PMID: 35857583
• Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies
  Minnar et al., Journal of Immunology (2022) - PMID: 35764364
  Product used: PepMix HPV 16 (E7)
• Robust SARS-COV-2-specific T-cell immune memory persists long-term in immunocompetent individuals post BNT162b2 double shot
  Papadopoulou et al., Heliyon (2022) - PMID: 35815135
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• A novel SARS-CoV-2 subunit vaccine engineered on an immune-activating platform technology
  Quinlan et al., Human Vaccines & Immunotherapeutics (2022) - PMID: 35801956
  Product used: PepMix SARS-CoV-2 (Spike-RBD)
• Safety and immunogenicity of intramuscular, single- dose V590 (rVSV-SARS-CoV-2 Vaccine) in healthy adults: Results from a phase 1 randomised, double- blind, placebo-controlled, dose-ranging trial
  Robbins et al., The Lancet (2022)
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• A Lymph Node Targeted Adjuvant and Engineered Subunit Vaccine Promotes Potent Immunity to Epstein-Barr Virus in HLA-expressing Mice
  Dasari et al., Research Square (2022)
  Product used: PepMix EBV (GP350/GP340)
• Longitudinal T Cell Responses against Ancestral, Delta, and Omicron SARS-CoV-2 Variants determined by Rapid Cytokine Release Assay in Whole Blood
  Oliver et al., Immunohorizons (2022) - PMID: 35750357
  Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SU1 & SU2), SARS-CoV-2 (Spike B.1.617/Delta),  SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron)
• Long-Lived Immunity in SARS-CoV-2-Recovered Children and Its Neutralizing Capacity Against Omicron
  Sieber et al., Frontiers in Immunology (2022) - PMID: 35663948
  Product used: PepMix SARS-CoV-2 (VME1), SARS-CoV-2 (VEMP), SARS-CoV-2 (NCAP),  SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron)
• Natural Immunity against HIV-1: Progression of Understanding after Association Studies
  Ma Luo, Viruses (2022) 
  Product used: PepMix HIV-1 (GAG) Ultra
• In Vitro Generation of BK polyomavirus-specifc T cells for adoptive cell therapy in refractory cystitis hemorrhagic patients after hematopoietic stem cell transplantation
  Najafabadi et al., BMC Immunology (2022) - PMID: 35689183
  Product used: PepMix BKV (Capsid Protein VP1)
• In Vitro Generation of BK polyomavirus-specifc T cells for adoptive cell therapy in refractory cystitis hemorrhagic patients after hematopoietic stem cell transplantation
  
• Najafabadi et al., BMC Immunology (2022) - PMID: 35689183
  Product used: 
• T-cell proliferation assay for the detection of SARS-CoV-2-specific T-cells
  Chu et al., Clinical Chimica Acta (2022) - PMID: 35690083
  Products used: PepMix SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (NCAP), SARS-CoV-2 (VME1)
• Pre-existing adaptive immunity to the RNA-editing enzyme Cas13d in humans
  Tang et al., Nature Medicine (2022) - PMID: 35668177
  Product used: PepMix S. pyogenes (CAS9)_2 subpools
• A DNA vaccine candidate delivered by an electroacupuncture machine provides protective immunity against SARS-CoV-2 infection
  Tzeng et al., Vaccines (2022)
• Chimeric Virus-like Particle-Based COVID-19 Vaccine Confers Strong Protection against SARS-CoV-2 Viremia in K18-hACE2 Mice
  Kaewborisuth et al., Vaccines (2022)
• Cellular Immune Response after Vaccination with an Adjuvanted, Recombinant Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients
  Koldehoff et al., Vaccines (2022)
• SARS-CoV-2 OmicronBA.1 variantbreakthrough infections in nursing home residentsafter an homologousthird dose of the Comirnaty® COVID-19 vaccine: Looking for correlates of protection
  Torres et al., Journal of Medical Virology (2022) 
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• Durable immunogenicity, adaptation to emerging variants and low dose efficacy of AAV-based COVID19 platform in macaques
  Zabaleta et al., Molecular Therapy (2022)
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• Enhanced Humoral Immune Response After COVID-19 Vaccination in Elderly Kidney Transplant Recipients on Everolimus Versus Mycophenolate Mofetil–containing Immunosuppressive Regimens
  de Boer et al., Translantation (2022) - PMID: 35546527
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• SARS-CoV2 wild type and mutant specific humoral and T cell immunity is superior after vaccination than after natural infection
  Richardson et al., PLoS One (2022) - PMID: 35468147
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (Spike B.1.1.7 / Alpha), SARS-CoV-2 (Spike B.1.351 / Beta), SARS-CoV-2 (Spike P.1 / Gamma), SARS-CoV-2 (Spike B.1.617.2 / Delta)
• Two DNA vaccines protect against severe disease and pathology due to SARS-CoV-2 in Syrian hamsters
  Babuadze et al., NPJ Vaccines (2022) - PMID: 35474311
  Product used: PepMix™ SARS-CoV (Spike Glycoprotein)
• Transcriptomic analysis reveals optimal cytokine combinations for SARS-CoV-2 Specific T cell therapy products
  Durkee-Shock et al., Molecular Therapy: Methods & Clinical Development (2022) 
• Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod
  Cabeza et al., Neurology: Neuroimmunology & Neuroinflammation - PMID: 35523569
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• Children and Adults With Mild COVID-19: Dynamics of the Memory T Cell Response up to 10 Months
  Kaaijk et al., Frontiers in Immunology (2022) 
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (NCAP), HCoV-OC43 (Spike Glycoprotein)
• Strong peak immunogenicity but rapid antibody waning following third vaccine dose in elderlyresidents of care homes
  Tut et al., Research Square (2022) 
  Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
• Discordant antibody and T cell responses to the SARS-CoV-2 Omicron variant in COVID-19 mRNA vaccine recipient
  Woldemeskel et al., Clinical Infectious Diseases (2022) - PMID: 35438751
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) & SARS-CoV-2 (S-RBD B.1.1.529 / Omicron)
• USA SARS-CoV-2 Epsilon Variant: Though Highly Transmissible has an Adjusted Muted Host T-Cell Response
  Plummer et al., Clinical Infectious Diseases (2022) - PMID: 35438777
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) & SARS-CoV-2 (Spike B.1.429 / Epsilon)
• mRNA booster vaccination protects extremely aged mice against the SARS-CoV-2 Omicron variant
  Dowling et al., Research Square (2022) 
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) & SARS-CoV-2 (S-RBD B.1.1.529 / Omicron)

• Evaluation of overcoming Limited migration and Enhancing Cytomegalovirus-specific dendritic cell Vaccines with Adjuvant TEtanus pre-conditioning in patients with newlydiagnosed glioblastoma
  Randazzo et al., Clinical Trials (2022)
  Product used: PepMix™ CMVA (pp65) 
• Viral Evolution and Immunology of SARS-CoV-2 in a Persistent Infection after Treatment with Rituximab
  van der Moerden et al., Viruses (2022) 
• Dynamics of SARS-CoV-2-Spike-reactive antibody and T-cell responses in chronic kidney disease patients within three months after COVID-19 full vaccination
  Panizo et al., Clinical Kidney Journal (2022) 
  Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
• Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): a single blind, randomized, non-inferiority trial
  Pannus et al., MedRxiv (2022)
• Safety and tolerability of AAV8 delivery of abroadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial
  Casazza et al., Nature Medicine (2022) - PMID: 35411076
  Product used: PepMix™ AAV8 (capsid protein)
• NK cells limit therapeutic vaccine–induced CD8+ T cell immunity in a PD-L1–dependent manner
  Diniz et al., Vaccines (2022) - PMID : 35417187
• Temporal changes in T cell subsets and expansion of cytotoxic CD4+ T cells in the lungs in severe COVID-19
  Kaneko et al., Clinical Immunology (2022) - PMID: 35364330
  Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
• T cell response against SARS-CoV-2 persists after one year in patients surviving severe COVID-19
  Venet et al., EBioMedicine (2022) - PMID: 35349827
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (NCAP), SARS-CoV-2 (VME1)
• CD4+ T Cell Dysfunction in Severe COVID-19 Disease is TNFalpha/TNFRI-Dependent
  Popescu et al., American Journal of Respiratory Critical Care Medicine - PMID: 35348444
  Products used: PepMix™ SARS-CoV-2 (NCAP), SARS-CoV-2 (VEMP), SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• The Quality of Anti-SARS-CoV-2 T Cell Responses Predicts the Neutralizing Antibody Titer in Convalescent Plasma Donors
  Kroemer et al., Front Public Health (2022) - PMID: 35372242
  Product used: PepMix™SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (NCAP), SARS-CoV-2 (VME1)
• High antibody and reduced cellular response in children up to one year after SARS-CoV-2 infection
  Jacobsen et al., Research Square (2022) 
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study
  Lim et al., Nature Cancer (2022) - PMID : 35332334
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• Self-amplifying mRNA SARS-CoV-2 vaccines raise cross-reactive immune response to variants and prevent infection in animal models
  Palladino et al., Methods and Clinical Development (2022)
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) & SARS-CoV-2 (NCAP) 
• Evolution of Humoral and Cellular Immunity in Two COVID-19 Breakthrough Infections After BNT162b2 Vaccine
  Gallais et al., Frontiers in Immunology (2022) - PMID: 35281046
  Products used: PepMix™ SARS-CoV-2 (Spike B.1.1.7 / Alpha), SARS-CoV-2 (Spike B.1.351 / Beta), SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• SARS‐CoV‐2 vaccination response in patients with autoimmune hepatitis and autoimmune cholestatic liver disease
  Duengelhoef et al., United European Gastroenterol Journal (2022) - PMID: 35289983
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
• Novel T cell interferon gamma release assay (IGRA) using spike recombinant protein for COVID19 vaccine response and Nucleocapsid for SARS-Cov2 response
  Renaudineau et al., Clinical Immunology (2022) - PMID: n.a.
  Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination
  Sheng et al., Journal of the Formosan Medical Association (2022) - PMID: 35305895
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• Modular capsid decoration boosts adenovirus vaccine-induced humoral and cellular immunity against SARS-CoV-2
  Dicks et al., BioRxiv (2022)
  Products used: PepMix™ SARS-CoV-2 (S-RBD), SARS-CoV-2 (Spike Glycoprotein)
• SARS-CoV- 2 (COVID- 19)-specific T cell and B cell responses in convalescent rheumatoid arthritis: Monozygotic twins pair case observation
  Arruda et al., Immunology (2022) - PMID: 35212005
  Products used: PepMix™ SARS-CoV-2 (NCAP) & SARS-CoV-2 (Spike Glycoprotein)
• Humoral and Cellular Immune Responses of Solid Organ Transplant Patients on Belatacept to Three Doses of mRNA-Based Anti-SARS-CoV-2 Vaccine
  Abravanel et al., Vaccines (2022) 
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
• Three-month follow-up of heterologous vs homologous third vaccination in kidney transplant recipients
  Heinzel et al., MedRxiv (2022)
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
• Limited Recognition of Highly Conserved Regions of SARS-CoV-2
  Swaminathan et al., Microbiology Spectrum (2022) - PMID: 35196796
  Products used: PepMix™ SARS-CoV-2 (Nsp12), SARS-CoV-2 (Spike Glycoprotein) & SARS-CoV-2 (NCAP)
• Assessment of humora land cellular immune responses to SARSCoV-2 vaccination (BNT162b2) inimmunocompromised renal allograft recipients
  Zhang et al., Transplant Infectious Diseases (2022)
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
• Tacrolimus-resistant SARS-CoV-2-specific T-cell products to prevent and treat severe COVID-19 in immunosuppressed patients
  Peter et al., Molecular Therapy (2022) 
  Products used: PepMix™ SARS-CoV-2 (NCAP), SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2), SARS-CoV-2 (VEMP), SARS-CoV-2 (VME1), SARS-CoV-2 (AP3A), SARS-CoV-2 (NS7A), SARS-CoV-2 (NS7B), SARS-CoV-2 (ORF9B), SARS-CoV-2 (ORF10), SARS-CoV-2 (Spike B.1.1.7 / Alpha), SARS-CoV-2 (Spike B.1.351 / Beta), SARS-CoV-2 (Spike B.1.617.2 / Delta), SARS-CoV-2 (Spike B.1.1.529 / Omicron), CMVA (pp65)
• Evaluation of IL-1β and IL-6 expression following EBNA-1 and BRLF-1 peptide treatment in Epstein Barr virus-positive multiple sclerosis patients
  Kianfar et al., Intervirology (2022)
• Performance comparison of a fow cytometry immunoassay for intracellular cytokine staining and the QuantiFERON® SARS-CoV-2test for detection and quantifcation of SARS-CoV-2-Spike-reactiveIFN-γ-producing T cells after COVID-19 vaccination
  Tormo et al., European Journal of Clinical Microbiology & Infectious Diseases (2022) - PMID: 35165804
  Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
• SARS-CoV-2-specific T cells generated for adoptive immunotherapy are capable of recognizing multiple SARS-CoV-2 variant
  Panikkar et al., Pathogens (2022) - PMID: 35157735
  Products used: PepMix™ SARS-CoV-2 (AP3A), SARS-CoV-2 (NCAP), SARS-CoV-2 (VME1), SARS-CoV-2 (Spike Glycoprotein)
• Polyfunctional pathogen-specific CD4+ T cells reside in the lungs and tumors of NSCLC patients
  Oja et al., BioRxiv (2022)
  Products used: PepMix™ HRSVB (Fusion Glycoprotein F0) & HRSVB (MSG)
• T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all prior infected and vaccinated individuals
  Vivek Naranbhai et al., MedRxiv (2022) - PMID: 35018386
  Products used:  PepMix™ SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (NCAP), SARS-CoV-2 (VME1), SARS-CoV-2 (VEMP), SARS-CoV-2 (AP3A), SARS-CoV-2 (Spike B.1.617.2 / Delta)
• Potent anti-viral activity of a trispecific HIV neutralizing antibody in SHIV-infected monkeys
  Amarendra Pegu et al., Cell Report (2022) - PMID: 34986348
  Products used: PepMix™ HIV-1 (ENV) Ultra
• Bystander CD4+ T cells infiltrate human tumors and are phenotypically distinct
  Shamin Li et al., OncoImmunology (2022) - PMID: n.a.
  Products used: PepMix™ CMVA (pp65)
• Innate and adaptive immune defects associated with lower SARS-CoV-2 BNT162b2 mRNA vaccine response in elderly people
  Joana Vitallé et al., medRxiv (2022) - PMID: n.a.
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
• Temporary hold of mycophenolate boosts SARS-CoV-2 vaccination-specific humoral and cellular immunity in kidney transplant recipients
  Eva Schrezenmeier et al., MedRxiv (2022) 
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
• Dynamics of spike-and nucleocapsid specific immunity during long-term follow-up and vaccination of SARS-CoV-2 convalescents
  Nina Koerber et al., Nature Communications (2022)
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
• Persistent T-Cell Reactivity in a Seronegative Patient after SARS-CoV-2 Infection and One Vaccination
  Nico Andreas et al., Vaccines (2022)
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity
  Shinya Abe et al., Immunotherapy of Cancer (2022)
  Products used: PepMix™ HIV-1 (GAG) Ultra
• Development of an effective immune response in adults with Down Syndrome 2 after SARS-CoV-2 vaccination
  Laura Esparcia-Pinedo et al., MedRxiv (2022) 
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2), SARS-CoV-2 (VME1), SARS-CoV-2 (NCAP), SARS-CoV-2 (Nsp5)
• Wnt activation promotes memory T cell polyfunctionality via epigenetic regulator PRMT1
  Bo-Yi Sung et al., Journal of Clinical Investigation (2022) - PMID: 35040433
  Products used: PepMix™ CMVA (pp65)
• Clinical and Immunological Characteristics for BK Polyomavirus- associated Nephropathy after Kidney Transplantation
  Tanaya Siripoon et al., Research Square (2022)
  Products used: PepMix™ BKV (capsid protein VP1), BKV (large T antigen)
• T cell response to intact SARS-CoV-2 includes coronavirus cross-reactive and variant-specific components
  Lichen Jing et al., MedRxiv et al., (2022)
  Products used: PepMix™ HCoV-OC43 (Spike Glycoprotein)
• Persistently reduced humoral and cellular immune response following third SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients
  Bajwa et al., MedRxiv (2022)
• Antibody and T cell responses to SARS-CoV-2 mRNA vaccines during maintenance therapy for immune-mediated inflammatory diseases
  Dayam et al., MedRxiv (2022)
• Infection or a third dose of mRNA vaccine elicit neutralizing antibody responses against SARS-CoV-2 in kidney transplant recipients
  Charmetant et al., Science Translational Medicine (2022) - PMID: 35103481
  Products used: PepMix™ SARS-CoV-2 (NCAP), SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (VME1)
• Concordance of B and T cell responses to SARS-CoV-2 infection, irrespective of symptoms suggestive of COVID-19
  Österdahl et al., MedRxiv (2022) 
• Differential localization and limited cytotoxic potential of duodenal CD8+ T cells
  Mvaya et al., JCI Insight (2022) - PMID: 35132966
  Products used: PepMix™ HIV-1 (POL), HIV-1 (GAG) & HIV-1 (NEF) 
• Full efficacy and long-term immunogenicity induced by the SARS-CoV-2 vaccine candidate MVA-CoV2-S in mice
  Lázaro-Frías et al., Vaccines (2022) 
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
• mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against Omicron
  Gagne et al., BioRxiv (2022)
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• A Co-stimulatory CAR Improves TCR-based Cancer Immunotherapy
  Omer et al., Cancer Immunology Research (2022) - PMID: 35176142
  Products used: PepMix™ EBV (EBNA1), EBV (LMP1), EBV (LMP2)
• Effectiveness and durability of the mRNA vaccine-induced SARSCoV-2-specific humoral and cellular immunity in severe asthma patients on biological therapy
  Prodrazil et al., MedRxiv (2022)
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
• Impaired Anti-SARS-CoV-2 Humoral and Cellular Immune Response Induced by Pfizer-BioNTech BNT162b2 mRNA Vaccine in Solid Organ Transplanted Patients
  Monica Miele et.al., American Journal of Transplantation (2021) - PMID: 34058052
• CD8+ T Cells Specific for an Immunodominant SARS-CoV-2 Nucleocapsid Epitope Cross-React With Selective Seasonal Coronaviruses
  Katie E Lineburg et.al., Immunity (2021) - PMID: 33945786
• Prime hAd5 Spike plus Nucleocapsid Vaccination Induces Ten-Fold Increases in Mean T-Cell Responses in Phase 1 Subjects that are Sustained Against Spike Variants
  Pete Sieling et.al., medRxiv (2021) - PMID: n.a.
• Gene Transfer in Adeno-Associated Virus Seropositive Rhesus Macaques Following Rapamycin Treatment and Subcutaneous Delivery of AAV6, but Not Retargeted AAV6 Vectors
  Stone et al., Human Gene Therapy (2021) - PMID: 32998579
  
• Preclinical Evaluation of a SARS-CoV-2 mRNA Vaccine PTX-COVID19-B
  Jun Liu et.al., bioRxiv (2021) - PMID: n.a.
• A Lymph Node-Targeted Amphiphile Vaccine Induces Potent Cellular and Humoral Immunity to SARS-CoV-2
  Martin P Steinbuck et.al., Sci Adv. (2021) - PMID: 33446655
• SARS-CoV-2 Spike Glycoprotein Vaccine Candidate NVX-CoV2373 Immunogenicity in Baboons and Protection in Mice
  Jing-Hui Tian et.al., Nat Commun (2021) - PMID: 33446655
• Safety and Immunogenicity of the SARS-CoV-2 BNT162b1 mRNA Vaccine in Younger and Older Chinese Adults: a Randomized, Placebo-Controlled, Double-Blind Phase 1 Study
  Jingxin Li et.al., Nat Med. (2021) - PMID: 33888900
• BNT162b Vaccines Protect Rhesus Macaques From SARS-CoV-2
  Annette B Vogel et.al., Nature (2021) - PMID: 33524990
• Older Adults Lack SARS CoV-2 Cross-Reactive T Lymphocytes Directed to Human Coronaviruses OC43 and NL63es
  Giulietta Saletti et.al., Sci Rep. (2021) - PMID: 33293664
• SARS-CoV-2 Variants of Concern Partially Escape Humoral but not T-Cell Responses in COVID-19 Convalescent Donors and Vaccinees
  Daryl Geers et.al., Sci Immunol. (2021) - PMID: 34035118
• COVID-19 Immune Signatures Reveal Stable Antiviral T Cell Function Despite Declining Humoral Responses
  Agnes Bonifacius et.al., Immunity (2021) - PMID: 33567252
• IL-33 Expression in Response to SARS-CoV-2 Correlates With Seropositivity in COVID-19 Convalescent Individuals
  Michal A Stanczak et.al., Nat Commun. (2021) - PMID: 33837219
• A Highly Specific Assay for the Detection of SARS-CoV-2-Reactive CD4 + and CD8 + T Cells in COVID-19 Patients
  Henning Zelba et.al., J Immunol. (2021) - PMID: 33298615
• SARS-CoV-2-Reactive T Cells in Healthy Donors and Patients With COVID-19
  Julian Braun et.al., Nature (2021) - PMID: 32726801
• Functional Characterization of CD4+ T Cell Receptors Crossreactive for SARS-CoV-2 and Endemic Coronaviruses
  Arbor G Dykema et.al., J Clin Invest. (2021) - PMID: 33830946
• Culture Media Optimization for Chinese Hamster Ovary Cell Growth and Expression of Recombinant Varicella-Zoster Virus Glycoprotein E
  Kwang Sung Kim et.al., Cytotechnology (2021) - PMID: 33897103
• SARS-CoV-2 Protein Subunit Vaccination of Mice and Rhesus Macaques Elicits Potent and Durable Neutralizing Antibody Responses
  Marco Mandolesi et.al., Cell Reports Medicine (2021) - PMID: 33842900
• SARS-CoV-2 mRNA Vaccine BNT162b2 Elicited a Robust Humoral and Cellular Response Against SARSCoV-2 Variants
  Daniele Lilleri et.al., Research Square (2021) - PMID: n.a.
• Children Develop Strong and Sustained Cross-Reactive Immune Responses Against Spike Protein Following SARS-CoV-2 Infection, With Enhanced Recognition of Variants of Concern
  Alexander C. Dowell et.al., medRxiv (2021) - PMID: n.a.
• Comorbid illnesses are associated with altered adaptive immune responses to SARS-CoV-2
  Krystle K.Q. Yu et.al., JCI Insight (2021) - PMID: 33621211
• Targeting SARS-CoV-2 Receptor-Binding Domain to Cells Expressing CD40 Improves Protection to Infection in Convalescent Macaques
  Romain Marlin et.al., Nature Communications (2021) - PMID: n.a.
• Characterization of Recombinant Gorilla Adenovirus HPV Therapeutic Vaccine PRGN-2009
  Samuel T. Pellom et.al., JCI Insight (2021) - PMID: 33651712
• Cytomegalovirus-Specific T-Cell Reconstitution Following Letermovir Prophylaxis after Hematopoietic Cell Transplantation
  Danniel Zamora et.al., In Press, Journal Pre-proof (2021) - PMID: 33657225
• Optimization of Zika DNA Vaccine by Delivery Systems
  Yun Ha Lee et.al., Virology (2021) - PMID: 33780719
• Human Cytomegalovirus and Epstein-Barr Virus Specific Immunity in Patients With Ulcerative Colitis
  Rachele Ciccocioppo et.al., Clinical and Experimental Medicine (2021) - PMID: 33772380
• Longitudinal Analysis of Human Memory T-Cell Response according to the Severity of Illness up to 8 Months after SARS-CoV-2 Infection
  Chang Kyung Kang et.al., The Journal of Infectious Diseases (2021) - PMID: 33755725
• Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection
  Jianmin Zuo et.al., Nature (2021) - PMID: 33674800
• SARS-CoV-2 Spike Protein Arrested In The Closed State Induces Potent Neutralizing Responses
  George W. Carnell et.al., bioRxiv (2021) - PMID: n.a.
• First Report Demonstrating The Safety And Immunogenicity Of The SARS-COV-2 BNT162b1 mRNA Vaccine In Younger And Older Chinese Adults: A Randomized, Placebo-Controlled, Observer-Blind Phase I Study
  Fengcai Zhu et.al., Research Square (2021) - PMID: n.a.
• Validation of an IFN-Gamma ELISpot Assay to Measure Cellular Immune Responses Against Viral Antigens in Non-Human Primates
  Fan Yang et.al., Gene Ther. (2021) - PMID: 33432123
• Poor Anti-SARS-CoV-2 Humoral and T-cell Responses After 2 Injections of mRNA Vaccine in Kidney Transplant Recipients Treated With Belatacept
  Nathalie Chavator et al., Transplantation, (2021)
• SARS-CoV-2 Specific Memory T Cell Epitopes Identified in COVID-19-Recovered Subjects
  Juan Zhao et al., Virus Res, (2021)
• Intrafamilial Exposure to SARS-CoV-2 Associated with Cellular Immune Response without Seroconversion, France
  Floriane Gallais et al., Emerg Infect Dis, (2021)
• SARS-CoV2 Mutant-Specific T Cells and Neutralizing Antibodies After Vaccination and up to 1 Year After Infection
  Richardson, J.R. et al., ISAR Bioscience, (2021)
• COVID-19 Subunit Vaccine with a Combination of TLR1/2 and TLR3 Agonists Induces Robust and Protective Immunity
  Soo-Kyung Jeong et al., Vaccines, (2021)
• M2-Deficient Single-Replication Influenza Vaccine–Induced Immune Responses Associated With Protection Against Human Challenge With Highly Drifted H3N2 Influenza Strain
  Joseph Eiden et al., J Infect Dis, (2021)
• Impairment of CD4+ T and Memory B Cell Responses but Normal Memory CD8+T-Cell Activation on Crohn’s Disease after COVID-19 Vaccination: A Twin Case
  Fabiana Gil-Melgaço et al., Viruses, (2021)
• Weak Immunogenicity of SARS-CoV-2 Vaccine in Patients With Hematologic Malignancies
  Florent Malard et al., Blood Cancer J, (2021)
• CD4+ T Cells of Prostate Cancer Patients Have Decreased Immune Responses to Antigens Derived From SARS-CoV-2 Spike
  Pavla Taborska et al., Front Immunol, (2021)
• T Cell–Mediated Response to SARS-CoV-2 in Liver Transplant Recipients With Prior COVID-19
  Mario Fernández-Ruiz et al., Am J Transplant, (2021)
• Prospective Assessment of SARS-CoV-2 Seroconversion (PASS) Study: an Observational Cohort Study of SARS-CoV-2 Infection and Vaccination in Healthcare Workers
  Jackson, B.M. et al., BMC Infect Dis, (2021)
• Cellular Immunity Predominates Over Humoral Immunity After Homologous and Heterologous mRNA and Vector-Based COVID-19 Vaccine Regimens in Solid Organ Transplant Recipients
  Tina Schmidt et al., Am J Translplant, (2021)
• The Legacy of Maternal SARS-CoV-2 Infection on the Immunology of the Neonate
  Sarah Gee et al., Nat Immunol, (2021)
• A Single-Cycle Influenza A Virus-Based SARS-CoV-2 Vaccine Elicits Potent Immune Responses in a Mouse Model
  Surapong Koonpaew et al., Vaccines, (2021)
• Impact of Multiple Sclerosis Disease-Modifying Therapies on SARS-CoV-2 Vaccine-Induced Antibody and T Cell Immunity
  Sabatino, J.J. et al., MedRxiv, (2021)
• Complete Protection of Nasal and Lung Airways Against SARS-CoV-2 Challenge by Antibody Plus Th1 Dominant N- and S-Specific T-Cell Responses to Subcutaneous Prime and Thermally-Stable Oral Boost Bivalent hAd5 Vaccination in an NHP Study
  Elizabeth Gabitzsch et al., BioRxiv, (2021)
• Cytomegalovirus-Specific Immunity Recovers More Slowly after Cord Blood Transplantation Compared with Matched Sibling Donor Allogeneic Transplantation
  Bejanyan, J. et al., Transplant Cell Ther, (2021)
• The Evaluation of Novel Oral Vaccines Based on Self-Amplifying RNA Lipid Nanparticles (saRNA LNPs), saRNA Transfected Lactobacillus Plantarum LNPs, and saRNA Transfected Lactobacillus Plantarum to Neutralize SARS-CoV-2 Variants Alpha and Delta
  Reza Keikha et al., Sci Rep, (2021)
• Single-Dose Intranasal Administration of AdCOVID Elicits Systemic and Mucosal Immunity against SARS-CoV-2 and Fully Protects Mice from Lethal Challenge
  King R.G. et al., Vaccines, (2021)
• T-Cell and Antibody Immunity After COVID-19 mRNA Vaccines in Healthy and Immunocompromised Subjects-An Exploratory Study
  Rakesh Sindhi et al., MedRxiv, (2021)
• SARS-CoV-2-Specific Antibody and T Cell Response Kinetics According to Symptom Severity
  Ji Yeun Kim et al., Am J Trop Med Hyg, (2021)
• Implementation of Adenovirus-Mediated Pulmonary Expression of Human ACE2 in HLA Transgenic Mice Enables Establishment of a COVID-19 Murine Model for Assessment of Immune Responses to SARS-CoV-2 Infection
  Theodor Chitlaru et al., Pathogens, (2021)
• Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase 1/2 Trial
  Punnee Pitisuttihum et al., MedRxiv, (2021)
• Protracted yet Coordinated Differentiation of Long-Lived SARS-CoV-2-Specific CD8+ T Cells During COVID-19 Convalescence
  Tongcui Ma et al., BioRxiv, (2021)
• SARS-Cov-2 Spike Protein Fragment 674–685 Protects Mitochondria From Releasing Cytochrome c in Response to Apoptogenic Influence
  Olena Kalashnyk et al., Biochem Biophys Res Commun, (2021)
• CD8+PD-L1+CXCR3+ Polyfunctional T Cell Abundances Are Associated With Survival in Critical SARS-CoV-2–Infected Patients
  Lucille Adam et al., JCI Insight, (2021)
• Protective Antibodies Elicited by SARS-CoV-2 Spike Protein Vaccination are Boosted in the Lung After Challenge in Nonhuman Primates
  Joseph R. Francica et al., Sci Transl Med, (2021)
• Profiling SARS-CoV-2 HLA-I Peptidome Reveals T Cell Epitopes From Out-of-Frame ORFs
  Shira Weingarten-Gabbay et al., Cell, (2021)
• A Short Corticosteroid Course Reduces Symptoms and Immunological Alterations Underlying Long-COVID
  Alberto Utrero-Rico et al., Biomedicines, (2021)
• COVID-19 Vaccine mRNA-1273 Elicits a Protective Immune Profile in Mice That is not Associated With Vaccine-Enhanced Disease Upon SARS-CoV-2 Challenge
  DiPiazza, A.T. et al., Immunity, (2021)
• Polymeric and Lipid Nanoparticles for Delivery of Self-Amplifying RNA Vaccines
  Blakney, A.K. et al., J Control Release, (2021)
• An Enveloped Virus-Like Particle Vaccine Expressing a Stabilized Prefusion form of the SARS-CoV-2 spike Protein Elicits Highly Potent Immunity
  Anne-Catherine Fluckiger et al., Vaccine, (2021)
• Intranasal Plus Subcutaneous Prime Vaccination With a Dual Antigen COVID-19 Vaccine Elicits T-Cell and Antibody Responses in Mice
  Adrian Rice et al., Sci Rep, (2021)
• Change in Symptoms and Immune Response in People with Post-Acute Sequelae of SARS-Cov-2 Infection (PASC) After SARS-Cov-2 Vaccination
  Daisy Massay et al., MedRxiv, (2021)
• Evolution of SARS-CoV-2 Immune Responses in Nursing Home Residents Following Full Dose of the Comirnaty® COVID-19 Vaccine
  Giménez, E. et al., J Infect (2021)
• Correlates of Neutralization against SARS-CoV-2 Variants of Concern by Early Pandemic Sera
  Vidal, S-J. et al., J Virol, (2021)
• Application of Spectral Library Prediction for Parallel Reaction Monitoring of Viral Peptides
  Grossegesse, M. et al., Proteomics, (2021)
• Preserved T-cell Response in anti-CD20 Treated Multiple Sclerosis Patients Following SARS-CoV-2 Vaccination
  Simon Faissner et al., Res Square, (2021)
• Durable T cell responses contrast with faster antibody waning in BNT162b2-vaccinated elderly at 6 month
  Laurent Renia et al., Res Square, (2021)
• SARS-CoV-2 ferritin nanoparticle vaccine induces robust innate immune activity driving polyfunctional spike-specific T cell responses
  Joshua M. Carmen et al., Vaccines, (2021)
• mRNA Vaccine Protects against Zika Virus
  Lex G. Medina-Magües et al., Vaccines, (2021)
• A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates
  M. Gordon Joyce et al., Science Translational Medicine
• SARS-CoV-2-Specific Cell-Mediated Immunity in Kidney Transplant Recipients Recovered From COVID-19
  Mario Fernández-Ruiz et al., Transplantation, (2021)
• First-in-Human Phase I Clinical Trial of an SFV-Based RNA Replicon Cancer Vaccine against HPV-Induced Cancers
  Fenne L. Komdeur et al., Mol Ther, (2021)
• SARS-CoV-2 Vaccination in Rituximab-Treated Patients: B Cells Promote Humoral Immune Responses in the Presence of T-Cell-Mediated Immunity
  Daniel Mrak et al., Ann Rheum Dis, (2021)
• Comorbid Illnesses are Associated With Altered Adaptive Immune Responses to SARS-CoV-2
  Krystle Kq Yu et al., JCI Insight, (2021)
• Longitudinal Analysis of Human Memory T-Cell Response According to the Severity of Illness up to 8 Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection
  Chang Kyung Kang et al., J Infect Dis, (2021)
• Deconvoluting the T Cell Response to SARS-CoV-2: Specificity Versus Chance and Cognate Cross-Reactivity
  Alexander A. Lehmann et al., Front Immunology, (2021)
• Identification of Conserved SARS-CoV-2 Spike Epitopes That Expand Public cTfh Clonotypes in Mild COVID-19 Patients
  Xiuyuan Lu et al., J Exp Med, (2021)
• Cytomegalovirus Specific Polyfunctional T-Cell Responses Expressing CD107a Predict control of CMV Infection After Liver Transplantation
  Ângela Carvalho-Gomes et al., Cellular Immunology, (2021)
• Off the Shelf Third Party Virus Specific T-Cell Therapy to Treat JC Polyomavirus Infection in Hematopoietic Stem Cell Transplant Recipients
  Jeremy D. Rubinstein et al., Transplant Cell Ther, (2021)
• Effectiveness of ChAdOx1 nCoV-19 Vaccine Against SARS-CoV-2 Infection During the Delta (B.1.617.2) Variant Surge in India: a Test-Negative, Case-Control Study and a Mechanistic Study of Post-Vaccination Immune Responses
  Ramachandran Thiruvengadam et al., Lancet Infect Dis, (2021)
• Rituximab impairs B-cell response but not T-cell response to COVID-19 vaccine in auto-immune diseases
  Samuel Bitoun et al., Arthritis & Rheumatology, (2021)
• Latent CMV Infection Is Associated With Lower Influenza Virus-Specific Memory T-Cell Frequencies, but Not With an Impaired T-Cell Response to Acute Influenza Virus Infection
  Sarah P.H. van den Berg et al., Front Immunology, (2021)
• Rituximab impairs B-cell response but not T-cell response to COVID-19 vaccine in auto-immune diseases
  Samuel Bitoun et al., Arthritis & Rheumatology (2021) - PMID: 34962357
• Latent CMV Infection Is Associated With Lower Influenza Virus-Specific Memory T-Cell Frequencies, but Not With an Impaired T-Cell Response to Acute Influenza Virus Infection
  Sara P H van den Berg et al., Front Immunology (2021) - PMID: 34025665

• CMV-Specific Immunity Recovers Slowly after Cord Blood Compared with Matched Sibling Donor Allogeneic Transplantation
  N.Bejanyan et.al., Transplantation and Cellular Therapy (2020) - PMID: n.a.
• Human Cytomegalovirus-Encoded microRNAs Can Be Found in Saliva Samples from Renal Transplant Recipients
  Shelley Waters et.al., Noncoding RNA. (2020) - PMID: 33353107
• Persistent Cellular Immunity to SARS-CoV-2 Infection
  Gaëlle Breton et.al., bioRxiv (2020) - PMID: 33330867
• Adaptive Immune Responses to SARS-CoV-2 in Recovered Severe COVID-19 Patients
  Beatriz Olea et.al., medRxiv (2020) - PMID: n.a.
• 1IL-2 and IFN-γ are Biomarkers of SARS-CoV-2 Specific Cellular Response in Whole Blood Stimulation Assays
  Begoña Pérez-Cabezas et.al., medRxiv (2020) - PMID: n.a.
• BNT162b2 Induces SARS-CoV-2-Neutralising Antibodies and T Cells in Humans
  Ugur Sahin et.al., medRxiv (2020) - PMID: n.a.
• Deconvoluting the T Cell Response to SARS-CoV-2: Specificity Versus Chance- and Cognate Cross-Reactivity
  Alexander A. Lehmann et.al., bioRxiv (2020) - PMID: n.a.
• Guidelines For Analysis of Low-Frequency Antigen-Specific T Cell Results: Dye-Based Proliferation Assay vs 3H-Thymidine Incorporation
  Daniela Di Blasi et.al., Journal of Immunological Methods (2020) - PMID: 33152332
• Antigenic Competition in the Generation of Multi-Virus-Specific Cell Lines for Immunotherapy of Human Cytomegalovirus, Polyomavirus BK, Epstein-Barr Virus and Adenovirus Infection in Haematopoietic Stem Cell Transplant Recipients
  Kateřina Roubalová et.al., Immunol Lett. (2020) - PMID: 33031870
• Convalescent Plasma Therapy for B-Cell Depleted Patients With Protracted COVID-19 Disease
  Thomas Hueso et.al., Blood (2020) - PMID: 32959052
• mRNA Based SARS-CoV-2 Vaccine Candidate CVnCoV Induces High Levels of Virus Neutralizing Antibodies and Mediates Protection in Rodents
  Susanne Rauch et.al., bioRxiv (2020) - PMID: n.a.
• Functional Immune Monitoring of BK Virus And Donor‐Specific T‐cell Effector Immune Responses to Guide Treatment Decision‐Making After Kidney Transplantation; an Illustrative Case Report And Literature Review
  Marta Lepore et.al., Transplant Infectious Disease (2020) - PMID: 33070461
• Divergent SARS‐CoV‐2‐Specific T and B Cell Responses in Severe but Not Mild COVID‐19 Patients
  Anna E. Oja et.al., European Journal of Immunology (2020) - PMID: 33073359
• Characteristicsof Rapamycin-Treated T Cell Products for Advanced Adoptive T Cell Therapy and Evaluation of Clinical Feasibility
  Leila Amini et.al., Dissertation (2020) - PMID: n.a.
• Intrafamilial Exposure to SARS-CoV-2 Induces Cellular Immune Response without Seroconversion
  Gallais F. et.al., Emerg Infect Dis (2020) - PMID: n.a.
• T Cell and Antibody Responses to SARS-CoV-2: Experience From a French Transplantation and Hemodialysis Center During the COVID-19 Pandemic
  Candon S. et.al., Am J Transplant (2020) - PMID: n.a.
• Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
  Evan J. Anderson et.al., New England Journal of Medicine (2020) - PMID: 32991794
• Single-Shot Ad26 Vaccine Protects Against SARS-CoV-2 in Rhesus Macaques
  Mercado et.al., Nature (2020) - PMID: 32731257
• Evaluation of the mRNA-1273 Vaccine Against SARS-CoV-2 in Nonhuman Primates
  Corbett et.al., N Engl J Med (2020) - PMID: 32722908
• Divergent SARS-CoV-2-Specific T and B Cell Responses in Severe but not Mild COVID-19
  Oja et.al., bioRxiv (2020) - PMID: n.a.
• Self-Amplifying RNA SARS-CoV-2 Lipid Nanoparticle Vaccine Candidate Induces High Neutralizing Antibody Titers in Mice
  McKay et.al., Nature (2020) - PMID: 32647131
• Generation of SARS-CoV-2 S1 Spike Glycoprotein Putative Antigenic Epitopes in Vitro by Intracellular Aminopeptidases
  Stamatakis et.al., bioRxiv (2020) - PMID: n.a.
• SARS-CoV-2-Specific T Cells Exhibit Unique Features Characterized by Robust Helper Function, Lack of Terminal Differentiation, and High Proliferative Potential
  Neidleman et.al., bioRxiv (2020) - PMID: 32577663
• A Longitudinal Study of Immune Cells in Severe COVID-19 Patients
  Payen et.al., medRXiv (2020) - PMID: n.a.
• SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness
  Corbett et.al., bioRxiv (2020) - PMID: 32577634
• Presence of SARS-CoV-2 Reactive T Cells in COVID-19 Patients and Healthy Donors
  Braun et.al., Nature (2020) - PMID: 32726801
• SARS‐CoV‐2‐Reactive Interferon‐γ‐Producing CD8+ T Cells in Patients Hospitalized with Coronavirus Disease 2019
  Estela Giménez et.al., Journal of Medical Virology (2020) - PMID: 32579268
• Evaluation of T-Activated Proteins as Recall Antigens to Monitor Epstein–Barr Virus and Human Cytomegalovirus-Specific T Cells in a Clinical Trial Setting
  Nina Körber et.al., Journal of Translational Medicine (2020) - PMID: 32552697
• Modified Alphavirus-Vesiculovirus Hybrid VaccineVectors for Homologous Prime-Boost Immunotherapyof Chronic Hepatitis B
  Carolina Chiale et.al., Vaccines (2020) - PMID: 32517032
• Duration of Cellular and Humoral Responses After Quadrivalent Human Papillomavirus Vaccination in Healthy Female Adultswith or Without Prior Type 16 and/or 18 Exposure
  Lilin Lai et.al., Vaccines (2020) - PMID: n.a.
• A SARS-CoV-2 mRNA Vaccine — Preliminary Report
  Lisa A Jackson et.al., N Engl J Med (2020) - PMID: 32663912
• HBV‐Specific CD8 T Cells Present Higher TNFα Expression But Lower Cytotoxicity in Hepatocellular Carcinoma
  Ludong Zhao et.al., Clinical & Experimental Immunology (2020) - PMID: 32474905
• Safety and Immunogenicity of a Zika Purified Inactivated Virus Vaccine Given Via Standard, Accelerated, or Shortened Schedules: a Single-Centre, Double-Blind, Sequential-Group, Randomised, Placebo-Controlled, Phase 1 Trial
  Kathryn E Stephenson et.al., The Lancet Infectious Diseases (2020) - PMID: n.a.
• Assessing Anti-HCMV Cell Mediated Immune Responses in Transplant Recipients and Healthy Controls Using a Novel Functional Assay
  Charlotte J. Houldcroft et.al., Cell-Mediated Immunity to HCMV (2020) - PMID: n.a.
• Evaluation of Glycoprotein E Subunit And Live Attenuatedvaricella‐Zoster Virus Vaccines Formulated With Asingle‐Strand RNA‐Based Adjuvant
  Su Jeen Lee et.al., Immunity, Inflammation and Disease (2020) - PMID: 32167678
• Women Who Received Varicella Vaccine Versus Natural Infection Have Different Long-Term T Cell Immunity but Similar Antibody Levels
  Ellen Tourtelot et.al., Vaccine (2020) - PMID: 31959424
• TGF‐β Promotes The Function Of HIV‐Specific CXCR5+CD8 T Cells
  Hong-Ge Yang et.al., Microbiology and Immunology (2020) - PMID: 32221997
• Persistent Expansion And Th1-Like Skewing of HIV-Specific Circulating T Follicular Helper Cells During Antiretroviral Therapy
  Julia Niessl Wu et.al., EBioMedicine (2020) - PMID: 32268275
• Preserved Specific Anti-Viral T-Cell Response But Associated With Decreased Lupus Activity In SLE Patients With Cytomegalovirus Infection
  Chien-Sheng Wu et.al., British Society for Rheumatology (2020) - PMID: 32306043
• A Chimeric Yellow Fever-Zika Virus Vaccinecandidate Fully Protects Against Yellow Fever Virusinfection in Mice
  Dieudonné Buh Kum et.al., Emerging Microbes & Infections (2020) - PMID: 32116148
• Efficacy, Immunogenicity, and Safety of an Oral Influenza Vaccine: a Placebo-Controlled And Active-Controlled Phase 2 Human Challenge Study
  David Liebowitz et.al., The Lancet Infectious Diseases (2020) - PMID: 31978354
• Immunogenicity of Novel mRNA COVID-19 Vaccine MRT5500 in Mice and 2 Non-Human Primates
  Kirill V. Kalnin et.al., Cancer Discovery (2019) - PMID: n.a.
• Tracking Dye‐Independent Approach to Identify and Isolate In Vitro Expanded T Cells
  George Elias et.al., Journal of Quantitative Cell Science (2019) - PMID: 31356002
• Adenovirus Vector-Based Vaccines Confer Maternal-Fetal Protection against Zika Virus Challenge in Pregnant IFN-αβR−/− Mice
  Rafael A.Larocca et.al., Clinical and Translational Report (2019) - PMID: 31668877
• Tumor-Infiltrating B Cells Affect the Progression of Oropharyngeal Squamous Cell Carcinoma Via Cell-To-Cell Interactions With CD8+ T Cells
  Kamila Hladikova et.al., Journal for ImmunoTherapy of Cancer (2019) - PMID: 31623665
• PD-1 Blockade and TLR7 Activationlack Therapeutic Benefit in Chronic SIV-Infected Macaqueson Antiretroviral Therapy
  Elena Bekerman et.al., Antimicrob. Agents Chemother. (2019) - PMID: 31501143
• Deciphering Effects of Uncontrolled Cytomegalovirus Replication on Immune Responses in Cytomegalovirus DNA-Positive Renal Transplant Recipients
  Nandini Makwana et.al., Viral Immunology (2019) - PMID: 31536468
• Generation of HPV-Specific T-Cells
  Carlos A. Ramos et.al., United States Patent Application 20190224302 (2019) - PMID: n.a.
• A Vaccine Based on Recombinant Modified Vaccinia Ankara Containing the Nucleoprotein from Lassa Virus Protects Against Disease Progression in a Guinea Pig Model
  E.M.Kennedy et.al., Vaccine (2019) - PMID: 31331770
• A Novel Simplified Method of Generating Cytomegalovirus-Specific Cytokine-Induced Killer Cells of High Specificity and Superior Potency with GMP Compliance
  Yen Hoon Luah et.al., Clinical Immunology (2019) - PMID: 31229666
• Generation of Zika Virus–Specific T Cells from Seropositive and Virus-Naïve Donors for Potential Use as an Autologous or “Off-the-Shelf” Immunotherapeutic
  Ryo Hanajiri et.al., Cytotherapy (2019) - PMID: n.a.
• HBeAg Seroconversion is Associated with a More Effective PD-L1 Blockade During Chronic Hepatitis B Infection
  Sara Ferrando-Martinez et.al., JHEP Reports (2019) - PMID: n.a.
• Enhancement of Immune Responses by Guanosine-Based Particles in DNA Plasmid Formulations against Infectious Diseases
  Saritza Santos et.al., Journal of Immunology Research (2019) - PMID: n.a.
• Prospective Assessment of CMV Immunity in High-Risk Donor Seropositive (D+) Recipient Seronegative (R-) Liver Transplant Recipients Receiving Either Preemptive Therapy or Prophylaxis
  Ajit P Limaye et.al. ,The Journal of Infectious Diseases (2019) - PMID: n.a.
• Phenotypic and Functional Differences Between HHV-6 and HCMV Specific T-Cells
  Solène Fastenackels et.al. , Journal of Virology (2019) - PMID: 30996090
• Evaluation of EBV- and HCMV-Specific T Cell Responses in Systemic Lupus Erythematosus (SLE) Patients Using a Normalized Enzyme-Linked Immunospot (ELISPOT) Assay
  Irene Cassaniti et.al. , PLoS Pathogens (2019) - PMID: n.a.
• T-Cell Responses Targeting HIV Nef Uniquely Correlate With Infected Cell Frequencies After Long-Term Antiretroviral Therapy
  Allison S. Thomas et.al. , PLoS Pathogens (2019) - PMID: 28931091
• Measurement of CD8.sup.+ and CD4.sup.+ T Cell Frequencies Specific for EBV LMP1 and LMP2a Using mRNA-Transfected DCs
  Dae-Hee Sohn et.al. , PLoS ONE (2019) - PMID: 26023769
• Efficient Induction of Cell-Mediated Immunity to Varicella-Zoster Virus Glycoprotein E Co-Lyophilized with a Cationic Liposome-Based Adjuvant in Mice
  Seo Ri Wui et.al. , Vaccine (2019) - PMID: 30827737
• Penalized Supervised Star Plots: Example Application in Influenza-Specific CD4+ T Cells
  Tyson H. Holmes et.al. , Viral Immunology (2019) - PMID: 30698511
• Antigen-Specific TCR Signatures of Cytomegalovirus Infection
  Alina Huth et.al. , The Journal of Immunology (2018) - PMID: 30587531
• Developmental Induction of Human T-cell Responses Against Candida Albicans and Aspergillus Fumigatus
  Katrin Vogel et.al. , Scientific Reportsvolume (2018) - PMID: 30442915
• Activation of Resident Memory T Cells for Cancer Immunotherapy
  Masopust Jr et.al. , United States Patent Application 20180325952 (2018) - PMID: n.a.
• Epstein-Barr Virus (EBV)-derived BARF1 Encodes CD4-and CD8-restricted Epitopes as Targets for T-cell Immunotherapy
  M Kalra et.al. , Cytotherapy (2018) - PMID: 30396848
• Generating HPV Antigen-specific Cells from a Native T Cell Population
  CM Bollard et.al. , US Patent App. 15/771,648, 2018 (2018) - PMID: n.a.
• Method For Preparing Genetically-Modified T Cells Which Express Chimeric Antigen Receptor
  Nishio et.al. , United States Patent Application 20180289742 (2018) - PMID: n.a.
• PI Highlight
  LL Kelley , PACT Newsletter (2018) - PMID: n.a.
• Replication Deficient Human Adenovirus Vector Serotype 19a/64: Immunogenicity in Mice and Female Cynomolgus Macaques
  Ragonnaud et al., Vaccine (2018) - PMID: 30190120
• Establishment and Operation of a Third Party Virus-Specific T-Cell Bank Within an Allogeneic Stem Cell Transplant Program
  Withers et al., Biology of Blood and Marrow Transplantation (2018) - PMID: 30172015
• Humoral and Cellular Immunity to RSV in Infants, Children and Adults
  Green et al., Vaccine (2018) - PMID: 30177258
• Altered CD4+ T‐Cell Immunity in Nurses Occupationally Exposed to Viral Pathogens
  Elias et al., Clin Exp Immunol (2018) - PMID: 30076783
• Dynamics of Virus‐Specific T Cell Immunity in Pediatric Liver Transplant Recipients
  Arasaratnam et al., American Journal of Transplantation (2018) - PMID: 29900673
• Pepmixes To Generate Multiviral Ctls With Broad Specificity
  Leen et al., US Patent App. 15/905,176, (2018) - PMID: n.a.
• Deleterious Effect of Steroids on Cytomegalovirus Infection Rate after Allogeneic Stem Cell Transplantation Depends on Pretransplant Cytomegalovirus Serostatus of Donors and Recipients
  Suárez-Lledó et al., Biology of Blood and Marrow Transplantation (2018) - PMID: 29753162
• Antiviral T Cells for Adenovirus in the Pretransplant Period: A Bridge Therapy for Severe Combined Immunodeficiency
  Miller et al., Biology of Blood and Marrow Transplantation (2018) - PMID: 29753156
• Employment of the Human Thymus as an Alternative Source of Regulatory T-Cells to Develop an Immunotherapy to Prevent Rejection in Transplanted Children
  Bernaldo de Quirós et al., Cytotherapy (2018) - PMID: n.a.
• Production of Quadrivalent Virus-Specific T Cells Utilizing Peptide Stimulation
  A. Damen et al., Cytotherapy (2018) - PMID: n.a.
• An Antigen-Free, Plasmacytoid Dendritic Cell–Targeting Immunotherapy To Bolster Memory CD8+ T Cells in Nonhuman Primates
  Masuta et al., J Immunol. (2018) - PMID: 29431693
• Multi-Antigenic Human Cytomegalovirus mRNA Vaccines that Elicit Potent Humoral and Cell-Mediated Immunity
  John et al., Sci Rep. (2018) - PMID: 29456015
• Cytomegalovirus-Specific T-Cells Are Associated with Immune Senescence, But Not With Systemic Inflammation, in People Living with HIV
  Ballegaard et al., Sci Rep. (2018) - PMID: 29491459
• Toward a Rapid Production of Multivirus-Specific T Cells Targeting BKV, Adenovirus, CMV, and EBV from Umbilical Cord Blood
  Corrales et al., Mol Ther Methods Clin Dev. (2017) - PMID: 28480300
• IL28B Genetic Variation and Cytomegalovirus-Specific T-cell Immunity in Allogeneic Stem Cell Transplant Recipients.
  Corrales et al., Journal of Medical Virology (2015) - PMID: 27591738
• Mycobacteria-Specific Cytokine Responses Detect TB Infection and Distinguish Latent from Active TB
  Tebruegge et al., Am J Respir Crit Care Med. (2015) - PMID: 26030187
• Method for Preparing Antigen-Specific Cytotoxic T-Cells by Using Activated B-Cells and use Thereof
  Kang et al., United States Patent Application 20180023054 (2018) - PMID: n.a.
• Production of Trivalent Antigen-Specific T Cells Utilizing Viral Peptide Stimulation
  Heyenbruch et al., Biology of Blood and Marrow Transplantation (2018) - PMID: n.a.
• Differential Expression of CD8+ T Cell Cytotoxic Effector Molecules in Blood and Gastrointestinal Mucosa in HIV-1 Infection
  Kiniry et al., The Journal of Immunology (2018) - PMID: 29352005
• "Cytomegalovirus (CMV) Immune Monitoring with ELISPOT and QuantiFERON-CMV Assay in Seropositive Kidney Transplant Recipients"
  Lee et al., Plos One (2017) - PMID: 29232714
• Asian Elephant T Cell Responses to Elephant Endotheliotropic Herpesvirus (EEHV)
  Fuery et al., Journal of Virology (2017) - PMID: 29263271
• Follistatin-Like Protein-1 Upregulates Dendritic Cell-Based Immunity in Patients with Nasopharyngeal Carcinoma
  Wang Hong et al., Journal of Interferon & Cytokine Research (2017) - PMID: 29135371
• Methods of Cell Culture for Adoptive Cell Therapy
  Vera et al., US Patent 20,170,267,973, 2017 (2017) - PMID: n.a.
• The Effect of Genetic Variants Affecting NK Cell Function on Cardiovascular Health and the Burden on CMV
  Waters et al., Hum Immunol. (2017) - PMID: 28987961
• Protein Structure Shapes Immunodominance in the CD4 T cell Response to Yellow Fever Vaccination
  Koblischke et al., Sci Rep. (2017) - PMID: 28827760
• Immunologic Profiling of Human Metapneumovirus (hMPV) Towards the Development of a Targeted Immunotherapy
  Tzannou et al., The Journal of Infectious Diseases (2017) - PMID: n.a
• Safety and Immunogenicity of a mRNA Rabies Vaccine in Healthy Adults: an Open-label, Non-randomised, Prospective, First-in-human Phase 1 Clinical Trial
  Alberer et al., Lancet. (2017) - PMID: 28754494
• Vorinostat Renders the Replication-Competent Latent Reservoir of Human Immunodeficiency Virus (HIV) Vulnerable to Clearance by CD8 T Cells
  Sung et al., EBioMedicine (2017) - PMID: 28803740
• CpG Oligonucleotides Increase HBV-Specific Cytokine Responses in Whole Blood and Enhance Cytokine Release Assay Sensitivity
  Dammermann et al., J Virol Methods (2017) - PMID: 28739303
• Elucidating CD8+ T-Cell Responses in the Rectal Mucosa During HIV Infection
  Kiniry et al., ProQuest (2017) - PMID: n.a.
• Vaccination with a Codon-Optimized A27L-Containing Plasmid Decreases Virus Replication and Dissemination After Vaccinia Virus Challenge
  Martínez et al., Vaccine (2017) - PMID: 28629922
• Pre-Transplant Immune Factors May be Associated with BK Polyomavirus Reactivation in Kidney Transplant Recipients
  DeWolfe et al., Plos one (2017) - PMID: 28562595
• Decitabine Treatment Sensitizes Tumor Cells to T-Cell-Mediated Cytotoxicity in Patients with Myelodysplastic Syndromes
  Zheng Zhang et al., Am J Transl Res (2017) - PMID: 28337274
• An Early Immediate Early Protein IE-1–Specific T-Cell Polyfunctionality Is Associated With a Better Control of Cytomegalovirus Reactivation in Kidney Transplantation
  Dekeyser et al., Kidney International Reports (2017) - PMID: n.a.
• Development of a Replication-Deficient Adenoviral Vector-Based Vaccine Candidate for the Interception of HPV16- and HPV18-Induced Infections and Disease
  Khan et al., International Jounal of Cancer (2017) - PMID: 28263390
• Breadth of T Cell Responses after Immunization with Adenovirus Vectors Encoding Ancestral Antigens or Polyvalent Papillomavirus Antigens
  Ragonnaud et al., Scandinavian Journal of Immunology (2017) - PMID: 28109028
• Primary Cytomegalovirus Infection in Seronegative Kidney Transplant Patients Is Associated with Protracted Cold Ischemic Time of Seropositive Donor Organs
  Schlott et al., Plos One (2017) - PMID: 28129395
• Perturbed CD8+ T Cell TIGIT/CD226/PVR Axis Despite Early Initiation of Antiretroviral Treatment in HIV Infected Individuals
  Tauriainen et al., Scientific Reports (2017) - PMID: 28084312
• Development of Novel Replication-defective Lymphocytic Choriomeningitis Virus Vectors Expressing SIV Antigens
  MacMaster et al., Vaccine (2016) - PMID: 27899229
• T Cells Infiltrating Diseased Liver Express Ligands for the NKG2D Stress Surveillance System
  Huang et al., Journal of Immunology (2016) - PMID: 28031333
• Polynucleotides For Treating Oncogenic Viral Polypeptide Positive Tumors
  Lee et al., US Patent 20,160,376,324 (2016) - PMID: n.a.
• Therapeutic Vaccine Targeting Epstein-Barr Virus Latent Protein, LMP1, Suppresses LMP1-Expressing Tumor Growth and Metastasis in Vivo
  Lin et al., BMC Cancer (2016) - PMID: 28056887
• Immune Monitoring to Predict and Prevent Infection
  Palmer et al., US Patent 20,160,377,602, 2016 (2016) - PMID: na.
• Predominance of Weakly Cytotoxic, T-betLowEomesNeg CD8+ T-Cells in Human Gastrointestinal Mucosa: Implications for HIV Infection.
  Kiniry et al., Mucosal Immunology (2016) - PMID: 27827375
• Expression of DAI by an Oncolytic Vaccinia Virus Boosts the Immunogenicity of the Virus and Enhances Antitumor Immunity
  Hirvinen et al., Molecular Therapy (2016) - PMID: 27626058
• αβ T Cell Receptor Germline CDR Regions Moderate Contact with MHC Ligands and Regulate Peptide Cross-Reactivity
  Attaf et al., Scientific Reports (2016) - PMID: 27775030
• Mapping the Sequence Space of ZIKA and Related Viruses: High-Content Peptide Libraries for Immune Monitoring
  von Hoegen et al., (2016) - PMID: n.a.
• The Challenge of Complexity: Peptide Tools for the Development of Immunotherapies
  Schnatbaum et al., (2016) - PMID: n.a.
• Circulating Functional T Cells Specific to HHV6 Antigens in Individuals With Chromosomally Integrated HHV-6 (ciHHV6)
  Barozzi et al., Clinical Microbiology and Infection (2016) - PMID: 27404369
• Human Papillomavirus 16 (HPV16) and HPV52 E6-Specific Immunity in HIV-Infected Adults on Combination Antiretroviral Therapy
  Leng et al., HIV Medicine (2016) - PMID: 27649852
• Immune Responses Elicited by the GEN-003 Candidate HSV-2 Therapeutic Vaccine in a Randomized Controlled Dose-Ranging Phase 1/2a Trial
  Flechtner et al., Vaccine (2016) - PMID: 27642130
• Functional Diversity of CMV-Specific T-Cells is Maintained in Older People and Significantly Associated with Protein Specificity and Response Size
  Bajwa et al., The Journal of Infetious Diseases (2016) - PMID: 27521364
• Self-Amplifying mRNA Vaccines Expressing Multiple Conserved Influenza Antigens Confer Protection against Homologous and Heterosubtypic Viral Challenge
  Magini et al., PloS one (2016) - PMID: 27525409
• Increased Frequency of BK Virus-Specific Polyfunctional CD8+ T Cells Predict Successful Control of BK Viremia After Kidney Transplantation
  Schaenman et al., Transplantation (2016) - PMID: 27391197
• Protective Efficacy of Multiple Vaccine Platforms Against Zika Virus Challenge in Rhesus Monkeys
  Abbink et al., Science (2016) - PMID: 27492477
• Distinct Metabolic Requirements of Exhausted and Functional Virus-Specific CD8 T Cells in the Same Host
  Schurich et al., Cell reports (2016) - PMID: 27452473
• Complementary Effects of IL-15 and IFN-α Induce Immunity in HBV Transgenic Mice
  Di Scala et al., Journal of virology (2016) - PMID: 27440883
• Composition and Dynamics of the Uterine NK Cell KIR Repertoire in Menstrual Blood
  Ivarsson et al., Mucosal Immunol. (2016) - PMID: 27271316
• Validation of an IFNγ/IL2 FluoroSpot Assay for Clinical Trial Monitoring
  Körber et al., J Transl Med. (2016) - PMID: 27297580
• A Single Exercise Bout Enhances the Manufacture of Viral-Specific T-cells from Healthy Donors: Implications for Allogeneic Adoptive Transfer Immunotherapy
  Spielmann et al., Sci Rep (2016) - PMID: 27181409
• Cellular Interferon Gamma and Granzyme B Responses to Cytomegalovirus-pp65 and Influenza N1 Are Positively Associated in Elderly
  Theeten et al., Viral Immunology (2016) - PMID: 27002465
• Reconstitution of Cytomegalovirus-Specific T-Cell Response in Allogeneic Hematopoietic Stem Cell Recipients: the Contribution of Six Frequently Recognized, Virus-Encoded ORFs
  Nemeckova et al., Transpl Infect Dis. (2016) - PMID: 27061389
• The VZV/IE63-Specific T Cell Response Prevents Herpes Zoster in Fingolimod-Treated Patients
  Mathias et al., Neurology (2016) - PMID: n.a.
• Cytotoxic Polyfunctionality Maturation of Cytomegalovirus-pp65-specific CD4+ and CD8+ T-cell Responses in Older Adults Positively Correlates with Response Size
  Chiu et al., Sci Rep. (2016) - PMID: 26778409
• Restoring Tissue-Like Functionality in Circulating CD8 T-Cells: Mechanistic Studies and Application in Immunomonitoring of Cancer Patients
  Wegner et al., Thesis for a doctoral degree at the Graduate School of Life Sciences, University Würzburg, Germany (2016) - PMID: n.a.
• In Vitro Studies of the Impact of Maribavir on CMV-Specific Cellular Immune Responses
  Stachel et al., J Clin Virol. (2015) - PMID: 26780109
• Generation of Broadly-Specific, Virus-Immune Cells Targeting Multiple HIV Antigens For Prenventive and Therapeutic Use
  Bollard et al., US Patent 20,150,359,876 (2015) - PMID: n.a.
• Recombinant Particle Based Vaccines Against Human Cytomegalovirus Infection
  Wellnitz et al., US Patent 20,150,359,879 (2015) - PMID: n.a.
• Induction Of Broad-Based Immunity and Protective Efficacy by Self-Amplifying mRNA Vaccines Encoding Influenza Virus Hemagglutinin
  Brazzoli et al., Journal of Virology (2015) - PMID: 26468547
• Functionally Active HIV-Specific T Cells that Target gag and nef Can Be Expanded from Virus-Naive Donors and Target a Range of Viral Epitopes: Implications for a Cure Strategy after Allogeneic HSCT
  Patel et al., Biology of Blood and Marrow Transplantation (2015) - PMID: n.a.
• Characteristics of Immune Memory 10–15 years After Primary Hepatitis B Vaccination
  Hummel et al., Vaccine (2015) - PMID: n.a.
• IL-12–Dependent Cytomegalovirus-Specific CD4+ T Cell Proliferation, T-bet Induction, and Effector Multifunction during Primary Infection Are Key Determinants for Early Immune Control
  Popescu et al., J Immunol. (2015) - PMID: 26663780
• Safety of Human Immunisation With a Live-attenuated Mycobacterium Tuberculosis Vaccine: a Randomised, Double-blind, Controlled Phase I Trial
  Spertini et al., The Lancet Respiratory Medicine (2015) - PMID: n.a
• Luciferase mRNA Transfection of Antigen Presenting Cells Permits Sensitive Non-radioactive Measurement of Cellular and Humoral Cytotoxicity
  Omokoko et al., Journal of Immunology Research (2015) - PMID: n.a.
• A Novel Lipid Nanoparticle Adjuvant Significantly Enhances B Cell and T Cell Responses to Sub-unit Vaccine Antigens
  Swaminathan et al., Vaccine (2015) - PMID: 26555351
• Peptide Libraries for the Comprehensive Coverage of the Tumor Mutanome for Immune Monitoring and Immuno Therapy
  von Hoegen et al., Journal for ImmunoTherapy of Cancer (2015)- PMID: n.a.
• Prognostic Impact of Circulating Her-2-reactive T-cells Producing Pro- and/or anti-inflammatory Cytokines in Elderly Breast Cancer Patients
  Bailur et al., J Immunother Cancer. (2015) - PMID: 26500775
• Targeting of Nucleoprotein to Chemokine Receptors by DNA Vaccination Results in Increased CD8+-mediated Cross Protection Against Influenza
  Baranowska et al., Vaccine (2015) - PMID: 26387432
• An Immunoinformatic Approach for Identification of Trypanosoma cruzi HLA-A2-Restricted CD8+ T cell Epitopes
  Eickhoff et al., Hum Vaccin Immunother. (2015) - PMID: 26107442
• Innate Immune Activity Correlates with CD4 T Cell-associated HIV-1 DNA Decline During Latency-Reversing Treatment with Panobinostat
  Olesen et al., Journal of Virology (2015) - PMID: 26223643
• Chimpanzee Adenovirus– and MVA-Vectored Respiratory Syncytial Virus Vaccine is Safe and Immunogenic in Adults
  Green et al., Science Translational Medicine. (2015) - PMID: n.a
• Efficacy of a Virus-Vectored Vaccine Against Human and Bovine Respiratory Syncytial Virus Infections
  Taylor et al., Science Translational Medicine. (2015) - PMID: n.a
• Immune Reconstitution After Allogeneic Hematopoietic Stem Cell Transplantation and Association With Occurrence and Outcome of Invasive Aspergillosis
  Stuehler et al., The Journal of Infectious Disease. (2015) - PMID: 25748323
• CD4+CD28null T Lymphocytes Resemble CD8+CD28null T Lymphocytes in Their Responses to IL-15 and IL-21 in HIV-infected Patients
  Echeverría et al., J. Leukoc. Biol. (2015) - PMID: 26034206
• Epstein-Barr Virus Reactivation Does Not Impact Total T-Cell Reconstitution But Is Associated With Decreased Functional T Cells after Stem Cell Transplantation
  Pietersma et al., J Clin Cell Immunol (2015) - PMID: n.a
• T Cells Specific for Different Latent and Lytic Viral Proteins Efficiently Control Epstein-Barr Virus–Transformed B Cells
  Nowakowska et al., Cytotherapy (2015) - PMID: 26276009
• Methods of Cell Culture for Adoptive Cell Therapy
  Vera et al., US Patent 20,150,175,966, 2015 - PMID: n.a
• High-Density Preculture of PBMCs Restores Defective Sensitivity of Circulating CD8 T Cells to Virus- and Tumor-derived Antigens
  Wegner et al., Blood (2015) - PMID: 26024876
• Metabolic Regulation of Hepatitis B Immunopathology by Myeloid-derived Suppressor Cells
  Pallett et al., Nature Medicine (2015) - PMID: 25962123
• ABO‐Desensitization Affects Cellular Immunity and Infection Control after Renal Transplantation
  Schachtner et al., Transplant International (2015) - PMID: 26033637
• The Tuberculosis Vaccine H4: IC31 is Safe and Induces a Persistent Polyfunctional CD4 T cell Response in South African Adults: A Randomized Controlled Trial
  Geldenhuys et al., Vaccine (2015) - PMID: 26048780
• Priming with a Simplified Intradermal HIV-1 DNA Vaccine Regimen followed by Boosting with Recombinant HIV-1 MVA Vaccine Is Safe and Immunogenic: A Phase Iia Randomized Clinical Trial
  Munseri et al., PloSOne (2015) - PMID: 25875843
• Comparing Humoral and Cellular Immune Response Against HBV Vaccine in Kidney Transplant Patients
  Friedrich et al., Am J Transplant. (2015) - PMID: 26137874
• Guidelines For the Automated Evaluation of Elispot Assays
  Janetzki et al., Nature Protocols (2015) - PMID: 26110715
• Peripheral Blood–Derived Virus-Specific Memory Stem T Cells Mature to Functional Effector Memory Subsets with Self-Renewal Potency
  Schmueck-Henneresse, The Journal of Immunology (2015) - PMID: 25917088
• A Comparative Phase 1 Clinical Trial to Identify Anti-infective Mechanisms of Vitamin D in People With HIV Infection
  Lachmann et al., AIDS (2015) - PMID: 25870995
• HCV-Specific Lymphocyte Responses in Individuals with Positive Anti-HCV but Negative HCV-RNA
  Sili et al., Journal of Clinical Virology (2015) - PMID: n.a.
• Safety and Immunogenicity of a Modified Vaccinia Ankara-based HIV-1 Vaccine (MVA-B) in HIV-1-Infected Patients Alone or in Combination with a Drug to Reactivate latent HIV-1
  Mothe et al., J Antimicrob Chemother. (2015) - PMID: 25724985
• A Single Bout of Dynamic Exercise by Healthy Adults Enhances the Generation of Monocyte-Derived-Dendritic Cells
  LaVoy et al., Cellular Immunology (2015) - PMID: n.a.
• Discordant Humoral and Cellular Immune Responses to Cytomegalovirus (CMV) in Glioblastoma Patients Whose Tumors are Positive for CMV
  Rahbar et al., OncoImmunology (2015) - PMID: n.a.
• Early Transduction Produces Highly Functional Chimeric Antigen Receptor-modified Virus-specific T-cells with Central Memory Markers: a Production Assistant for Cell Therapy (PACT) Translational Application
  Sun et al., J Immunother Cancer. (2015) - PMID: 25734008
• Role of Naïve-Derived T Memory Stem Cells in T Cell Reconstitution Following Allogeneic Transplantation
  Roberto et al., Blood. (2015) - PMID: 25742699
• Multispecific Aspergillus T Cells Selected by CD137 or CD154 Induce Protective Immune Responses Against the Most Relevant Mold Infections
  Stuehler et al., The Journal of Infectious Disease (2015) - PMID: 25367298
• Mycobacterium Tuberculosis-Specific and MHC Class I-Restricted CD8+ T-Cells Exhibit a Stem Cell Precursor-Like Phenotype in Patients with Active Pulmonary Tuberculosis
  Axelsson-Robertson et al., Int J Infect Dis. (2015) - PMID: 25809750
• The Loss of BKV-Specific Immunity From Pretransplantation to Posttransplantation Identifies Kidney Transplant Recipients at Increased Risk of BKV Replication
  Schachtner et al., Am J Transplant. (2015) - PMID: 25808077
• Diagnostics Reagents
  Jones et al., US Patent 20,150,093,766 (2015) - PMID: n.a.
• CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells
  Wang et al., Clin Cancer Res. (2015) - PMID: 25838392
• Selection of Adenovirus-specific and Epstein-Barr virus–specific T Cells With Major Histocompatibility Class I Streptamers Under Good Manufacturing Practice (GMP)–Compliant Conditions
  Freimüller et al., Cytotherapy (2015) - PMID: 25866178
• Cutting Edge: Identification and Characterization of Human Intrahepatic CD49a+ NK Cells
  Marquardt et al., J Immunol. (2015) - PMID: 25672754
• Potential role of CC Chemokine Receptor 6 (CCR6) in Prediction of Late‐onset CMV Infection Following Solid Organ Transplant
  Camargo et al., Clin Transplant. (2015) - PMID: 25690781
• Polynucleotides for Treating Oncogenic Viral polypeptide Positive Tumors
  Lee et al., US Patent 20,150,023,996, (2015) - PMID: n.a.
• Functional Exhaustion limits CD4+ and CD8+ T Cell Responses to Congenital Cytomegalovirus Infection
  Huygens et al., J Infect Dis. (2015) - PMID: 25657256
• Early Exposure to Interleukin-21 Limits Rapidly Generated Anti–Epstein-Barr Virus T-cell Line Differentiation
  Orio et al., Cytotherapy. (2015) - PMID: 25661862
• STAT3 Signaling Contributes to the High Effector Activities of Interleukin-15-derived Dendritic Cells
  Okada et al., Immunol Cell Biol. (2015) - PMID: 25582338
• Human Papillomavirus 16-Specific T-Cell Responses and Spontaneous Regression of Anal High-Grade Squamous Intraepithelial Lesions
  Tong et al., J Infect Dis. (2015) - PMID: 25139018
• Intracellular Cytokine Staining on PBMCs Using CyTOFTM Mass Cytometry
  Lin et al., bio-protocol.org - PMID: n.a.
• The External Quality Assurance Oversight Laboratory (EQAPOL) Proficiency Program for IFN-gamma Enzyme-Linked ImmunoSpot (IFN-γ ELISpot) Assay
  Sanchez et al., J Immunol Methods. (2014) - PMID: n.a.
• Establishment and Maintenance of a PBMC Repository for Functional Cellular Studies in Support of Clinical Vaccine Trials
  Sambor et al., J Immunol Methods. (2014) - PMID: 24787274
• CMV Specific Cytokine Release Assay in Whole Blood is Optimized by Combining Synthetic CMV Peptides and Toll Like Receptor Agonists
  Dammermann et al., Journal of Immunological Methods (2014) - PMID: n.a.
• Naïve and Memory CD8 T Cell Pool Homeostasis in Advanced Aging: Impact of Age and of Antigen-specificRresponses to Cytomegalovirus
  Vescovini et al., Age (Dordr). (2014) - PMID: 24318918
• Preformed Frequencies of Cytomegalovirus (CMV)–Specific Memory T and B Cells Identify Protected CMV-Sensitized Individuals Among Seronegative Kidney Transplant Recipients
  Lúcia et al., Clinical Infectious Diseases (2014) - PMID: 25048845
• A Recombinant Modified Vaccinia Ankara Vaccine Encoding Epstein–Barr Virus (EBV) Target Antigens: A Phase I Trial in UK Patients with EBV-Positive Cancer
  Taylor et al., Clin. Cancer Res. (2014) - PMID: 25124688
• Human B Cells Produce Chemokine CXCL10 in the Presence of Mycobacterium Tuberculosis Specific T Cells
  Hoff et al., Tuberculosis (2014) - PMID: n.a.
• Expression of the Human Cytomegalovirus UL11 Glycoprotein in Viral Infection and Evaluation of its Effect on Virus-Specific CD8 T Cells
  Gabaev et al., Journal of Virology (2014) - PMID: 25275132
• HPV16-Specific T-Cell Responses and Spontaneous Regression of Anal High-Grade Squamous Intraepithelial Lesions
  Tong et al., J Infect Dis. (2014) - PMID: 25139018
• Immune Responses Againgst Mycobacterium Tuberculosis Targets Associated to Latent and Active Tuberculosis Infection
  Montserrat Alvarez-Corrales, Published by Karolinska Institutet (2014) - PMID: n.a.
• Preferential Infection of Human Ad5-Specific CD4 T Cells by HIV in Ad5 Naturally Exposed and Recombinant Ad5-HIV Vaccinated Individuals
  Hu et al., PNAS (2014) - PMID: 25197078
• Diminished Humoral Responses Against and Reduced Gene Expression Levels of Human Endogenous Retrovirus-K (HERV-K) in Psoriasis
  Gupta et al., Journal of Translational Medicine (2014) - PMID: 25224121
• Gene Therapy for Rhesus Monkeys Heterozygous for LDL Receptor Deficiency by Balloon Catheter Hepatic Delivery of Helper-Dependent Adenoviral Vector
  Oka et al., Gene Therapy (2014) - PMID: 25231173
• Superior In Vitro Stimulation of Human CD8+ T-Cells by Whole Virus versus Split Virus Influenza Vaccines
  Halbroth et al., PLoS One (2014) - PMID: PLoS One (2014)
• Activity of Broad-Spectrum T Cells as Treatment for AdV, EBV, CMV, BKV, and HHV6 Infections After HSCT
  Papadopoulou et al., Sci Transl Med. (2014) - PMID: 24964991
• Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation
  Fourati et al., JoVE (2014) - PMID: 25046399
• The Role of CD4+ T Cells in BKV-Specific T Cell Immunity
  Weist et al., Med Microbiol Immunol. (2014) - PMID: 25052009
• NetFCM: A Semi-Automated Web-Based Method for Flow Cytometry Data Analysis
  Frederiksen et al., Cytometry A. (2014) - PMID: 25044796
• T-Bet and Eomes Are Differentially Linked to the Exhausted Phenotype of CD8+ T Cells in HIV Infection
  Buggert et al., PLoS Pathog. (2014) - PMID: 25032686
• Specificities of Human CD4+ T Cell Responses to an Inactivated Flavivirus Vaccine and Infection: Correlation with Structure and Epitope Prediction
  Schwaiger et al., J Virol. (2014) - PMID: 24789782
• Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19-IL2 Results in Sustained Clinical and Systemic Immunological Responses
  Weide et al., American Association for Cancer Research (2014) - PMID: n.a
• BK Polyomavirus‐Specific Cellular Immune Responses Are Age‐Dependent and Strongly Correlate With Phases of Virus Replication
  Schmidt et al., American Journal of Transplantation (2014) - PMID: 24726000
• MART-1 Peptide Vaccination Plus IMP321 (LAG-3Ig fusion protein) in Patients Receiving Autologous PBMCs After Lymphodepletion: Results of a Phase I Trial
  Romano et al., Journal of Translational Medicine (2014) - PMID: 24726012
• TLR2-Dependent Protection Against Pneumococcal Carriage by Immunization with Lipidated Pneumococcal Proteins
  Moffitt et al., Infection and Immunol. (2014) - PMID: 24614661
• An Enzyme-Linked Immunospot Assay for the Detection of Human Respiratory Syncytial Virus F-Specific IFNγ-producing T Cells
  Patton et al., Clin Vaccine Immunol. (2014) - PMID: 24574540
• Influence of Frequent Infectious Exposures on General and Varicella-zoster Virus Specific Immune Responses in Pediatricians
  Ogunjimi et al., Clin Vaccine Immunol. (2014) - PMID: 24429070
• Deficient EBV-Specific B- and T-Cell Response in Patients with Chronic Fatigue Syndrome
  Loebl et al., PLOS ONE (2014) - PMID: 24454857
• HIV Infection in Uncircumcised Men Is Associated With Altered CD8 T-cell Function But Normal CD4 T-cell Numbers in the Foreskin
  Prodger et al., The Journal of Infectious Diseases (2014) - PMID: 24277744
• Sustained Complete Responses in Patients With Lymphoma Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein-Barr Virus Latent Membrane Proteins
  Bollard et al., J Clin Oncol. (2013) - PMID: 24344220
• Cytomegalovirus Vaccine Strain Towne-Derived Dense Bodies Induce Broad Cellular Immune Responses and Neutralizing Antibodies that Prevent Infection of Fibroblasts and Epithelial Cells
  Cayatte et al., J. of Virology (2013) - PMID: 23926341
• Mechanistic Insights Into the Impairment of Memory B Cells and Antibody Production in the Elderly
  Aberle et al., AGE (2013) - PMID: 22282053
• Detection of Epstein-Barr Virus-Specific Memory CD4+ T Cells Using a Peptide-Based Cultured Enzyme-Linked Immunospot Assay
  Calarota et al., Immunology (2013) - PMID: 23560877
• Nonreplicating Vaccines Can Protect African Green Monkeys from the Memphis 37 Strain of Respiratory Syncytial Virus
  Eyles et al., Journal of Infectious Diseases (2013) - PMID: 23596321
• Overnight Resting of PBMC Changes Functional Signatures of Antigen Specific T- Cell Responses: Impact for Immune Monitoring within Clinical Trials
  Kutscher et al., PLoS One (2013) - PMID: 24146841
• Inflammatory Activation and Recovering BKV-specific Immunity Correlate with Self-Limited BKV Replication after Renal Transplantation
  Schachtner et al., Transplant International (2013) - PMID: 24279642
• Adoptive Immunotherapy with Antigen-Specific T Cells During Extracorporeal Membrane Oxygenation (ECMO) for Adenovirus-Related Respiratory Failure in a Child Given Haploidentical Stem Cell Transplantatio
  Di Nardo et al., Pediatric Blood & Cancer (2013) - PMID: 24039155
• Rapid Generation of EBV-Specific Cytotoxic T Lymphocytes Resistant to Calcineurin Inhibitors for Adoptive Immunotherapy
  Ricciardelli et al., American Journal of Transplantation (2013) - PMID: 24266973
• The Immunogenicity of Virus-Derived 2A Sequences in Immunocompetent Individuals
  Arber et al., Gene Therapy (2013) - PMID: 23698740
• Adoptive T-Cell Transfer and Chemotherapy in the First-Line Treatment of Metastatic and/or Locally Recurrent Nasopharyngeal Carcinoma
  Chia et al., Molecular Therapy (2013) - PMID: 24297049
• Combination of Epstein-Barr Virus Nuclear Antigen 1, 3 and Lytic Antigen BZLF1 Peptide Pools Allows Fast and Efficient Stimulation of Epstein-Barr Virus-Specific T Cells for Adoptive Immunotherapy
  Wang et al., Cytotherapy (2013) - PMID: 24094498
• A Novel Cytomegalovirus-Induced Regulatory-Type T-Cell Subset Increases in Size During Older Life and Links Virus-Specific Immunity to Vascular Pathology
  Terrazzini et al., The Journal of Infectious Disease (2013) - PMID: 24203779
• Putting Polyphosphates to the Test: Evidence Against Platelet-Induced Activation of Factor XII
  Faxälv et al., Blood (2013) - PMID: 23896408
• Short-Term In-Vitro Expansion Improves Monitoring and Allows Affordable Generation of Virus-Specific T-Cells against Several Viruses for a Broad Clinical Application
  Geyeregger et al., PLOS ONE (2013) - PMID: 23630567
• Adoptive Transfer of Epstein-Barr Virus (EBV) Nuclear Antigen 1–Specific T Cells As Treatment for EBV Reactivation and Lymphoproliferative Disorders After Allogeneic Stem-Cell Transplantation
  Icheva et al., JCO (2013) - PMID: 23169501
• Human Papillomavirus Type 16 E6/E7-Specific Cytotoxic T Lymphocytes for Adoptive Immunotherapy of HPV-Associated Malignancies
  Ramos et al., Journal of Immunotherapy (2013) - PMID: 23211628
• Cytomegalovirus-Specific CD4 and CD8 T Cell Responses in Infants and Children
  Lidehäll et al., Scandinavian Journal of Immunology (2013) - PMID: 23216075
• The Effects of Age and Latent Cytomegalovirus Infection on the Redeployment of CD8+ T Cell Subsets in Response to Acute Exercise in Humans
  Spielmann et al., Brain, Behavior, and Immunity (2013) - PMID: 23684819
• The Third Signal Cytokine IL-12 Rescues the Anti-Viral Function of Exhausted HBV-Specific CD8 T Cells
  Schurich et al., PLOS Pathogens (2013) - PMID: 23516358
• Antibody Quality and Protection from Lethal Ebola Virus Challenge in Nonhuman Primates Immunized with Rabies Virus Based Bivalent Vaccine
  Blaney et al., PLOS Pathogens (2013) - PMID: 23737747
• Donor-Derived CMV-Specific T Cells Reduce The Requirement For CMV-Directed Pharmacotherapy After Allogeneic Stem Cell Transplantation
  Blyth et al., Blood. (2013) - PMID: 23435462
• Antigen-Reactive T Cell Enrichment for Direct, High-Resolution Analysis of the Human Naive and Memory Th Cell Repertoire
  Bacher et al., J. Immunol. (2013) - PMID: 23479226
• An Adjuvanted Herpes Simplex Virus 2 Subunit Vaccine Elicits a T Cell Response in Mice and Is an Effective Therapeutic Vaccine in Guinea Pigs
  Skoberne et al., J. Virol. (2013) - PMID: 23365421
• Distinct Gene-Expression Profiles Associated With the Susceptibility of Pathogen-Specific CD4 T Cells to HIV-1 Infection
  Hu et al., Blood. (2013) - PMID: 23258923
• IL-7– and IL-15–Mediated TCR Sensitization Enables T Cell Responses to Self-Antigens
  Deshpande et al., J. Immunol. (2013) - PMID: 23325887
• Up-Regulation of a Death Receptor Renders Antiviral T Cells Susceptible to NK Cell–Mediated Deletion
  Peppa et al., J. Exp. Med. (2012) - PMID: 23254287
• Reconstitution of Protective Immune Responses against Cytomegalovirus and Varicella Zoster Virus Does Not Require Disease Development in Pediatric Recipients of Umbilical Cord Blood Transplantation
  Merindol et al., J. Immunol. (2012) - PMID: 23034171
• Antiviral T Cell Response Triggers Cytomegalovirus Hepatitis in Mice
  Livingston-Rosanoff et al., J. Virol. (2012) - PMID: 22993151
• Full-Length HIV-1 Immunogens Induce Greater Magnitude and Comparable Breadth of T Lymphocyte Responses to Conserved HIV-1 Regions Compared with Conserved-Region-Only HIV-1 Immunogens in Rhesus Monkeys
  Stephenson et al., J. Virol. (2012) - PMID: 22896617
• Polyclonal Mucosa-Associated Invariant T Cells Have Unique Innate Functions in Bacterial Infection
  Chua et al., Infect. Immun. (2012) - PMID: 22778103
• Differential Patterns of Large Tumor Antigen-Specific Immune Responsiveness in Patients with BK Polyomavirus-Positive Prostate Cancer or Benign Prostatic Hyperplasia
  Sais et al., J. Virol. (2012) - PMID: 22647697
• Single-Cell Level Response of HIV-Specific and Cytomegalovirus-Specific CD4 T Cells Correlate With Viral Control in Chronic HIV-1 Subtype A Infection
  Eller et al., J Acquir Immune Defic Syndr (2012) - PMID: 22580564
• A Novel Th Cell Epitope of Candida albicans Mediates Protection from Fungal Infection
  Bär et al., J. Immunol. (2012) - PMID: 22529294
• Three Sensitive Assays Do Not Provide Evidence for Circulating HuD-specific T Cells in the Blood of Patients with Paraneoplastic Neurological Syndromes with Anti-Hu Antibodies
  de Jongste et al., Neuro Oncology. (2012) - PMID: 22591661
• Performance of the QuantiFERON-Cytomegalovirus (CMV) Assay for Detection and Estimation of the Magnitude and Functionality of the CMV-Specific Gamma Interferon-Producing CD8+ T-Cell Response in Allogeneic Stem Cell Transplant Recipients
  Clari et al., Clin Vaccine Immunol May (2012) - PMID: 22379065
• The Thai Phase III Trial (RV144) Vaccine Regimen Induces T Cell Responses That Preferentially Target Epitopes within the V2 Region of HIV-1 Envelope
  de Souza et al., J. Immunol. (2012) - PMID: 22529301
• Preferential Expansion of Human Virus-Specific Multifunctional Central Memory T Cells by Partial Targeting of the IL-2 Receptor Signaling Pathway: The Key Role of CD4+ T Cells
  Schmueck et al., J. Immunol. (2012) - PMID: 22516956
• T-Cell Therapy for EBV-Associated Nasopharyngeal Carcinoma: Preparative Lymphodepleting Chemotherapy Does not Improve Clinical Results
  Secondino et al., Ann. Onc. (2012) - PMID: 21586688
• A Whole Blood Monokine-Based Reporter Assay Provides a Sensitive and Robust Measurement of the Antigen-Specific T Cell Response
  Chakera et al., Journal of Translational Medicine (2011) - PMID: 21871084
• Live and Inactivated Influenza Vaccines Induce Similar Humoral Responses, but Only Live Vaccines Induce Diverse T-Cell Responses in Young Children
  Hoft et al., The Journal of Infectious Disease (2011) - PMID: 21846636
• Rebound of Residual Plasma Viremia After Initial Decrease Following Addition of Intravenous Immunoglobulin to Effective Antiretroviral Treatment of HIV
  Mellberg et al., AIDS Research and Therapy (2011) - PMID: 21708049
• A Phase II Study Evaluating the Safety and Efficacy of an Adenovirus-LMP1-LMP2 Transduced Dendritic Cell Vaccine in Patients with Advanced Metastatic Nasopharyngeal Carcinoma
  Chia et al., Ann. Onc. (2011) - PMID: 21821548
• Polyomavirus BK Large T-Antigen Derived Peptide Elicits a HLA-DR Promiscuous and Polyfunctional CD4+ T-cell Response
  Ramaswami et al., Clin. Vaccine Immunol (2011) - PMID: 21367979
• Expansion of T Cells Targeting Multiple Antigens of Cytomegalovirus, Epstein – Barr Virus and Adenovirus to Provide Broad Antiviral Specificity After Stem Cell Transplantation
  Hanley et al., Cytotherapy (2011) - PMID: 21539497
• Adoptive Transfer of EBV-Specific T Cells Results in Sustained Clinical Responses in Patients With Locoregional Nasopharyngeal Carcinoma
  Louis et al., J Immunother (2010) - PMID: 20948438
• Effective and Long-Term Control of EBV PTLD After Transfer of Peptide-Selected T Cells
  Moosmann et al., Blood (2010) - PMID: 20103780
• Accelerated Production of Antigen-Specific T-Cells for Pre-Clinical and Clinical Applications Using Gas-permeable Rapid Expansion Cultureware (G-Rex)
  Vera et al., J Immunother. (2010) - PMID: 20445351
• Derivation of Human T Lymphocytes From Cord Blood and Peripheral Blood with Antiviral and Antileukemic Specificity from a Single Culture as Protection Against Infection and Relapse after Stem Cell Transplantation
  Micklethwaite et al., Blood (2010) - PMID: 20110422
• Absence of Systemic Immune Response to Adenovectors After Intraocular Administration to Children With Retinoblastoma
  Ildefonso et al., Molecular Therapy (2010) - PMID: 20606647
• Nucleofection of DCs to Generate Multivirusspecific T Cells for Prevention or Treatment of Viral Infections in the Immunocompromised Host
  Gerdemann et al., Molecular Therapy (2009) - PMID: 19584818
• Cytotoxic T Lymphocyte Therapy with Donor T Cells Prevents and Treats Adenovirus and Epstein-Barr Virus Infections after Haploidentical and Matched Unrelated Stem Cell Transplantation
  Leen et al., Blood (2009) - PMID: 19700662
• Tuberculosis Subunit Vaccination Provides Long-Term Protective Immunity Characterized by Multifunctional CD4 Memory T Cells
  Lindenstrom et al., J. Immunol (2009) - PMID: 19494330
• Enhancing the In Vivo Expansion of Adoptively Transferred EBV-Specific CTL with Lymphodepleting CD45 Monoclonal Antibodies in NPC Patients
  Louis et al., Blood (2009) - PMID: 18971421
• Mesenchymal Stem Cells Exert Differential Effects on Alloantigen and Virus-Specific T-cell Responses
  Karlsson et al., Blood (2008) - PMID: 18445691
• Prospective Monitoring of Polyomavirus BK Replication and Impact of Pre-Emptive Intervention in Pediatric Kidney Recipients
  Ginevri et al., American Journal of Transplantation (2007) - PMID: 17908275
• Contact-Activated Monocytes: Efficient Antigen Presenting Cells for the Stimulation of Antigen-specific T cells
  Leen et al., J Immunother (2007) - PMID: 17198088